clomiPRAMINE (Monograph)

Brand name: Anafranil
Drug class: Tricyclics and Other Norepinephrine-reuptake Inhibitors
VA class: CN601
Chemical name: 3-Chloro-10,11-dihydro-N,N-dimethyl -5H-dibenz[b,f]azepine-5-propanamine monohydrochloride
Molecular formula: C₁₉H₂₃ClN₂•HCl
CAS number: 17321-77-6

Medically reviewed by Drugs.com on May 22, 2024. Written by ASHP.

Warning

Antidepressants may increase risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18–24 years of age) with major depressive disorder and other psychiatric disorders; balance this risk with clinical need.^d ^e Clomipramine is not approved for use in pediatric patients except patients with obsessive-compulsive disorder.¹ (See Pediatric Use under Cautions.)
In pooled data analyses, risk of suicidality was not increased in adults >24 years of age and apparently was reduced in adults ≥65 years of age with antidepressant therapy compared with placebo.^d ^e
Depression and certain other psychiatric disorders are themselves associated with an increased risk of suicide.^d ^e ^f
Appropriately monitor and closely observe all patients who are started on clomipramine therapy for clinical worsening, suicidality, or unusual changes in behavior; involve family members and/or caregivers in this process.^d ^e ^f (See Worsening of Depression and Suicidality Risk under Cautions.)

Introduction

Tricyclic antidepressant (TCA);¹ ² ³ ²³⁵ pharmacologic profile resembles that of other TCAs,²³⁵ ²³⁸ SSRIs, and trazodone.² ³ ⁴ ²¹² ²¹³ ²¹⁴ ²²⁰ ²²¹

Uses for clomiPRAMINE

Obsessive-Compulsive Disorder (OCD)

Among the drugs of choice for the management of OCD.⁶⁹ ²⁸⁹ ²⁹³ ²⁹⁶ ²⁹⁷

Reduces but does not completely eliminate obsessions and compulsions.⁹⁶ ²⁷¹ ²⁹² ³⁰⁰

Panic Disorder

Has been used effectively for the management of panic disorder^{† [off-label]} with or without agoraphobia^{† [off-label]}.² ³ ⁴ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ¹⁰⁷ ¹⁰⁸ ¹⁰⁹ ¹¹⁰ ¹¹⁶ ³⁴⁷

Major Depressive Disorder

Has been used effectively for the management of major depressive disorder^{† [off-label]}.² ³ ²⁵⁴ ²⁵⁵ ²⁵⁶ ²⁵⁷ ²⁵⁸ ²⁵⁹ ²⁶⁰ ²⁶⁷ ²⁷⁷ ²⁷⁸ ²⁸² ²⁸⁸

Despite comparable efficacy,² ³ ²⁵⁵ ²⁵⁶ ²⁵⁷ ²⁵⁸ ²⁶⁰ ²⁷⁷ ²⁸² ²⁸³ the adverse effect profile (e.g., anticholinergic effects) of clomipramine may limit its usefulness relative to other antidepressants (e.g., TCAs, SSRIs).² ²⁵⁷ ²⁵⁸ ²⁷⁷ ²⁸² ²⁸³ ²⁸⁸ ²⁸⁹

Effective antidepressant when obsessive manifestations accompany episode of major depressive disorder.²⁸⁸

Chronic Pain

Has been used for the management of chronic pain^{† [off-label]} (e.g., central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, cancer pain) alone or as adjunct to conventional analgesics.² ³ ⁵² ¹¹¹ ¹¹² ¹¹³ ¹¹⁴ ¹¹⁵ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹²¹ ¹²² ¹²³ ¹²⁴ ¹²⁵ ³⁴³ ³⁴⁴

Cataplexy and Associated Narcolepsy

Has been used for the symptomatic management of cataplexy^{† [off-label]} in a limited number of patients with cataplexy^† and associated narcolepsy^†.³ ¹³² ¹³³ ²⁷⁹

Autistic Disorder

Has been used for the management of repetitive and obsessive-compulsive behaviors and hyperactivity associated with autistic disorder^†;¹³⁴ ¹³⁵ ¹⁴¹ ²⁸⁵ ²⁸⁶ does not treat core symptoms of autistic disorder.^b

Trichotillomania

Has been used for the management of trichotillomania^† (an urge to pull out one’s hair) in a limited number of patients with the disorder;³ ¹³⁶ ¹³⁷ ¹³⁸ ¹³⁹ relapse reported in some patients receiving long-term therapy.¹⁴⁰

Onychophagia

Has been used for the management of severe onychophagia^† (nail biting) without a history of OCD.¹⁴²

Associated with relatively high dropout rate because of adverse effects and drug intolerance; not considered first-line therapy in most patients with onychophagia.¹⁴² ³⁴¹

Eating Disorders

Has been used for the management of anorexia nervosa^† in a limited number of patients with the disorder.²²⁹ ²³⁰ ²³¹

Initial therapeutic effects (e.g., improved eating behavior, weight gain) not sustained with long-term therapy (e.g., ≥8 weeks).²²⁹ ²³⁰ ²³¹ ²³⁴

Avoid use in underweight individuals and in those exhibiting suicidal ideation.²⁸⁸ ³⁴¹

Premature Ejaculation

Has been used for the management of premature ejaculation^†.³ ¹²⁸ ¹²⁹ ¹³⁰ ¹³¹

Premenstrual Syndrome

Has been used for the management of premenstrual syndrome^†.²⁶¹ ²⁶² ²⁶³ ²⁶⁴

clomiPRAMINE Dosage and Administration

General

Allow at least 2 weeks to elapse between discontinuance of therapy with an MAO inhibitor and initiation of clomipramine and vice versa.¹ Also allow at least 5 weeks to elapse when switching from fluoxetine.¹
Monitor for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustments.^d ^e ^f (See Worsening of Depression and Suicidality Risk under Cautions.)
Sustained therapy may be required;² ⁴ ³³ ⁷⁸ ⁸⁰ ⁸¹ ⁸² ¹⁴⁸ ³⁴¹ use lowest effective dosage and monitor periodically for need for continued therapy.¹ ²⁹⁹
Avoid abrupt discontinuance of therapy.¹ ² ⁷⁸ ¹⁴⁸ ³⁰¹ To avoid withdrawal reactions, taper dosage gradually (e.g., over a period of approximately 2 weeks).¹ ² ⁷⁸ ¹⁴⁸ ³⁰¹

Panic Disorder†

Transient increase in the number and intensity of panic attacks may occur during initial therapy with the drug.⁴ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ²⁸⁸

Administration

Oral Administration

Administer orally; initially, in divided doses with meals to lessen adverse GI effects.¹ After initial dosage titration, the total daily dose may be given once daily at bedtime¹ ² ⁴ ²⁷¹ to minimize adverse effects (e.g., sedation) during waking hours¹ ² and enhance patient compliance.²

Also has been administered IM^† or IV^†, but a parenteral dosage form is not commercially available in the US.⁴ ²⁷²

Dosage

Available as clomipramine hydrochloride; dosage is expressed in terms of the salt.¹

Individualize dosage carefully according to individual requirements and response.¹

Allow 2–3 weeks to elapse between any further dosage adjustments after the initial dosage titration period for achievement of steady-state plasma concentrations.¹

Pediatric Patients

OCD

Oral

Children >10 years of age: initially, 25 mg daily.¹ Gradually increase dosage, as tolerated, during the first 2 weeks of therapy up to a maximum of 3 mg/kg or 100 mg daily, whichever is lower.¹ ² ²⁴² Titrate dosage carefully.¹ If necessary, dosages may be increased gradually during the next several weeks up to a maximum of 3 mg/kg or 200 mg daily (whichever is lower).¹ ² ³ ⁴ ⁶⁶ ⁶⁷

Optimum duration not established; ¹ ⁷⁸ ²⁷¹ some clinicians recommend that therapy be continued in responding patients at the minimally effective dosage for at least 18 months before attempting to discontinue.¹ ²⁷¹ ²⁹⁹

Adults

OCD

Oral

Initially, 25 mg daily.¹ Gradually increase dosage, as tolerated, during the first 2 weeks of therapy to approximately 100 mg daily.¹ If necessary, dosages may be increased gradually during the next several weeks up to a maximum of 250 mg daily.¹ ² ³ ⁴ ⁶⁶ ⁶⁷

Panic Disorder†

Oral

Usual dosage: ≤50 mg daily (range: 12.5–150 mg daily);² ⁴ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ¹⁰⁷ ¹⁰⁸ ¹¹⁰ ¹¹⁶ ²⁷² patients with agoraphobia may require higher dosage.⁴ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶

Major Depressive Disorder†

Oral

100–250 mg daily.² ²⁷² ²⁷⁷ ²⁷⁸ ²⁸⁸

Chronic Pain†

Oral

100–250 mg daily.² ¹¹⁵ ²⁷² ²⁸⁸

Cataplexy and Associated Narcolepsy†

Oral

25–200 mg daily.¹³² ¹³³ ²⁷² ²⁷⁹

Prescribing Limits

Pediatric Patients

OCD

Oral

Maximum 3 mg/kg or 200 mg daily, whichever is lower.¹ ² ³ ⁴ ⁶⁶ ⁶⁷

Adults

OCD

Oral

Maximum 250 mg daily.¹ ² ³ ⁴ ⁶⁶ ⁶⁷

Panic Disorder†

Oral

Maximum 200 mg daily.² ⁴ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ¹⁰⁷ ¹⁰⁸ ¹¹⁰ ¹¹⁶ ²⁷²

Special Populations

Geriatric Patients

Manufacturer makes no specific recommendation for dosage adjustment¹ ⁴¹ ²⁴⁰ but lower clomipramine hydrochloride dosages are recommended by some clinicians at least during initial therapy.² ⁴ ²⁷² ²⁸²

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.¹

Cautions for clomiPRAMINE

Contraindications

Concurrent or recent (i.e., within 2 weeks) therapy with an MAO inhibitor.¹ (See Specific Drugs under Interactions.)
During the acute recovery phase following MI.¹
Known hypersensitivity to clomipramine or other TCAs.¹

Warnings/Precautions

Warnings

Seizures

Risk of seizure; use with caution in patients with a history of seizures or other predisposing factors (e.g., brain damage of various etiology, alcoholism, concurrent use of other drugs that lower the seizure threshold).¹

Risk may be dose related.¹ (See Prescribing Limits under Dosage and Administration.)

Worsening of Depression and Suicidality Risk

Possible worsening of depression and/or emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior in both adult and pediatric patients, whether or not they are taking antidepressants; may persist until clinically important remission occurs.^d ^e ^f ^g However, suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.^d ^e ^f

Appropriately monitor and closely observe patients receiving clomipramine for any reason, particularly during initiation of therapy (i.e., the first few months) and during periods of dosage adjustments.^d ^e ^f (See Boxed Warning and also see Pediatric Use under Cautions.)

Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and/or mania may be precursors to emerging suicidality.^e ^f Consider changing or discontinuing therapy in patients whose depression is persistently worse or in those with emerging suicidality or symptoms that might be precursors to worsening depression or suicidality, particularly if severe, abrupt in onset, or not part of patient’s presenting symptoms.^d ^e ^f (See General under Dosage and Administration and also see Withdrawal Reactions under Cautions.)

Prescribe in smallest quantity consistent with good patient management to reduce risk of overdosage.¹ ^e

Observe these precautions for patients with psychiatric (e.g., major depressive disorder, OCD) or nonpsychiatric disorders.^e

Bipolar Disorder

May unmask bipolar disorder.^e (See Activation of Mania or Hypomania under Cautions.) Clomipramine is not approved for use in treating bipolar depression.¹

Screen for risk of bipolar disorder by obtaining detailed psychiatric history (e.g., family history of suicide, bipolar disorder, depression) prior to initiating therapy.^e

General Precautions

Cardiovascular Effects

Modest orthostatic decreases in BP,¹ ¹⁹³ modest tachycardia,¹ and/or ECG abnormalities (e.g., VPCs, ST-T wave changes, intraventricular conduction abnormalities) reported; use with caution in patients with known cardiovascular disease.¹

Titrate dosage carefully.¹

Neuropsychiatric Effects

Variety of neuropsychiatric manifestations (e.g., delusions, hallucinations, psychotic episodes, confusion, paranoia) reported.¹ ³ ¹⁵⁵ ¹⁵⁶ ²³⁸

May precipitate an acute psychotic episode in patients with unrecognized schizophrenia.¹ ³ ¹⁵⁵ ¹⁵⁶ ²⁹⁵

Activation of Mania or Hypomania

Risk of activation of mania or hypomania in patients with affective disorder.¹ ³ ¹⁵⁵ ¹⁵⁶ ²⁹⁵ (See Bipolar Disorder under Cautions.)

Anticholinergic Effects

Use with caution in patients for whom excess anticholinergic activity could be harmful (e.g., history of urinary retention, increased intraocular pressure, angle-closure glaucoma).¹

Interactions

More than 30 cases of hyperthermia reported,¹ most cases occurring in patients receiving clomipramine in combination with other drugs (e.g., antipsychotic agents).¹ ¹⁵⁷ ¹⁹⁹ When clomipramine and an antipsychotic agent were used concomitantly, the cases sometimes were considered to be examples of neuroleptic malignant syndrome (NMS).¹ ¹⁵⁷ ¹⁹⁹

Hepatic Effects

Potentially clinically important elevations (e.g., >3 times ULN) in serum ALT¹ ⁶⁵ and AST¹ concentrations;¹ severe hepatic injury and/or death rarely reported.¹

Possible cross hepatotoxicity (e.g., elevated values on hepatic function tests, abdominal pain) involving different TCAs including clomipramine.²⁰⁷ (See Hepatic Impairment under Cautions.)

Hematologic Effects

Bone marrow depression¹ ²²⁷ (e.g., leukopenia,¹ agranulocytosis,¹ ³ ¹⁶² ¹⁶⁴ ¹⁶⁵ ¹⁶⁶ thrombocytopenia,¹ anemia,¹ pancytopenia)¹ ³ ¹⁶³ rarely reported.¹ ²²⁷

Obtain leukocyte and differential blood cell counts if fever and sore throat occur during therapy.¹

Sexual Dysfunction

Relatively high risk of sexual dysfunction¹ ³ ¹⁸⁰ (e.g., libido change,¹ ⁶⁵ ¹⁸⁹ ²⁵¹ ejaculatory failure,¹ ⁶⁵ ¹⁸⁰ ¹⁸⁸ ²⁵¹ impotence¹ ⁶⁵ ¹⁸⁹ ²⁴⁵ ²⁷⁰ ) in male patients with OCD.¹

Normal sexual functioning usually returns within a few days after discontinuing therapy.² ³ ¹⁸⁰

Weight Changes

Possible weight gain¹ ²⁴² ²⁴⁵ ²⁴⁷ ²⁴⁹ or weight loss.¹

Withdrawal Reactions

Withdrawal reactions (e.g., dizziness, nausea, vomiting, headache, malaise, sleep disturbance, hyperthermia, sweating, irritability, seizures, worsening of psychiatric status) reported following abrupt discontinuance of therapy.¹ ² ⁷⁸ ¹⁴⁸ ³⁰¹

To avoid withdrawal reactions, taper dosage gradually and monitor patients carefully.¹ ² ⁷⁸ ¹⁴⁸ ³⁰¹

Electroconvulsive Therapy (ECT)

Possible increased ECT risks; limit to patients for whom concomitant use is essential.¹

Elective Surgery

Discontinue therapy for as long as is clinically feasible prior to surgery and advise the anesthetist of such action.¹

Thyroid Disease

Use with caution in hyperthyroid patients or patients receiving thyroid agents because of the possibility of cardiac toxicity.¹ ¹

Adrenal Medulla Tumors

Use with caution in patients with tumors of the adrenal medulla, in whom hypertensive crises may be provoked.¹

Specific Populations

Pregnancy

Category C.¹

Possible withdrawal symptoms (e.g., jitteriness,¹ ⁷¹ ¹⁵² ¹⁵⁸ tremor,¹ ⁷¹ ¹⁵³ ¹⁵⁴ seizures¹ ³ ¹⁵² ¹⁵³ ) in neonates whose mothers received clomipramine throughout pregnancy;¹ avoid use during late pregnancy whenever possible.¹⁵³

Lactation

Distributed into milk;¹ ⁴ ²² ⁵⁵ ⁶⁰ ⁶² ⁷¹ ¹⁵⁰ discontinue nursing or the drug.¹ ⁶² ¹⁴⁹ ¹⁵⁰ ¹⁵¹

Pediatric Use

Safety and efficacy for OCD not established in children <10 years of age.¹

Potential risks associated with long-term use (e.g., effects on growth, development, or maturation) not systematically evaluated in children and adolescents.¹

Adverse effects in children and adolescents >10 years of age generally similar to those in adults.¹

FDA warns that a greater risk of suicidal thinking or behavior (suicidality) occurred during first few months of antidepressant treatment (4%) compared with placebo (2%) in children and adolescents with major depressive disorder, OCD, or other psychiatric disorders based on pooled analyses of 24 short-term placebo-controlled trials of 9 antidepressant drugs (SSRIs and others).^e However, a more recent meta-analysis of 27 placebo-controlled trials of 9 antidepressants (SSRIs and others) in patients <19 years of age with major depressive disorder, OCD, or non-OCD anxiety disorders suggests that the benefits of antidepressant therapy in treating these conditions may outweigh the risks of suicidal behavior or suicidal ideation.^g No suicides occurred in these pediatric trials.^e ^g

Carefully consider these findings when assessing potential benefits and risks of clomipramine in a child or adolescent for any clinical use.^d ^e ^f ^g (See Worsening of Depression and Suicidality Risk under Cautions.)

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.¹

In pooled data analyses, a reduced risk of suicidality was observed in adults ≥65 years of age with antidepressant therapy compared with placebo.^d ^e (See Boxed Warning and also see Worsening of Depression and Suicidality Risk under Cautions.)

Possible increased sensitivity to anticholinergic (e.g., dry mouth, constipation, vision disturbance), cardiovascular, orthostatic hypotension, and sedative effects of TCAs.^h ⁱ ^j ^k

Hepatic Impairment

Use with caution in patients with clinically important hepatic disease; periodically monitor hepatic enzyme concentrations.¹

Renal Impairment

Use with caution in patients with clinically important renal impairment.¹

Common Adverse Effects

Adverse GI (e.g., dry mouth, constipation, nausea, dyspepsia, anorexia, increased appetite), nervous system (e.g., somnolence, tremor, dizziness, nervousness, fatigue, myoclonus), or genitourinary (e.g., changed libido, ejaculatory failure, impotence, micturition disorder) effects; sweating; weight gain; visual changes.¹ ² ³⁵ ⁶⁵ ²⁴²

Drug Interactions

Extensively metabolized in the liver by various CYP isoenzymes (e.g., CYP1A2,³⁴⁶ CYP2C,⁷³ CYP2D6,⁷² ⁷³ CYP3A4).^c

Drugs Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP2D6 and/or 1A2: Potential pharmacokinetic interaction (increased plasma clomipramine concentrations).^a Monitor plasma clomipramine concentrations whenever a CYP2D6 inhibitor is added or discontinued and adjust dosages as needed.^a

Drugs Associated with Serotonin Syndrome

Potential pharmacologic (serotonin syndrome) interaction with serotonergic agents.¹ ¹⁷⁵ ³⁰² ³⁰³ Avoid such use whenever clinically possible.¹ ³⁰² ³⁰³

Drugs Affecting the Seizure Threshold

Use caution with concurrent administration of clomipramine and drugs (e.g., other antidepressants, antipsychotic agents) that lower the seizure threshold.¹

Protein-bound Drugs

Potential for clomipramine to displace or to be displaced by other protein-bound drugs.¹ Observe patients for adverse effects.¹ ²

Specific Drugs

Drug	Interaction	Comments
Alcohol	Potential for increased CNS effects of alcohol¹ Limited data suggest that demethylation of clomipramine may be reduced with chronic alcohol consumption⁵⁵ ⁶⁰ ⁶³ ⁶⁴	Advise patients of risks of such concomitant use¹
Alprazolam	Adverse effects resembling serotonin syndrome¹⁷⁴ ¹⁷⁸
Antiarrhythmics: class 1C (e.g., flecainide, propafenone)	Potential for decreased clomipramine metabolism^a	Monitor for TCA toxicity^a
Anticholinergic agents	Potential for additive anticholinergic effects¹ ² ^c	Use with caution; dosage adjustment may be needed¹ ² ^c
Antipsychotic agents (e.g., phenothiazines)	Hyperthermia and adverse effects resembling NMS¹ ¹⁵⁷ ¹⁹⁹ Potential for decreased clomipramine metabolism^c	Dosage adjustment may be needed^c
Barbiturates (e.g., phenobarbital)	May be additive with or may potentiate CNS effects¹ ¹⁵⁹ Possible decreased plasma clomipramine concentrations¹ ¹⁵⁹ Increased plasma phenobarbital concentrations reported¹	Advise patients of risks associated with such concomitant use¹
Cimetidine	Potential increased plasma clomipramine concentrations¹ ¹⁵⁹ ^c	Use with caution; dosage adjustment may be needed^c
CNS depressants (e.g., alcohol, sedatives, hypnotics)	Potentiates effects of CNS depressants¹ ^c	Use with caution^c
Digoxin	Possible altered protein binding of clomipramine or digoxin¹ ²	Monitor for adverse effects¹ ²
Haloperidol	Potential for increased plasma clomipramine concentrations¹ ²	Use with caution; dosage adjustment may be needed^c
Hypotensive agents (e.g., clonidine, guanethidine)	May antagonize antihypertensive effects¹ ² ¹⁵⁹	Monitor BP^c
Levodopa	May interfere with levodopa absorption^c	Monitor levodopa dosage carefully^c
Lithium	Adverse effects resembling serotonin syndrome¹⁷⁴ ¹⁷⁸
MAO inhibitors (e.g., phenelzine)	Potentially life-threatening serotonin syndrome¹ ² ¹⁵⁹ ¹⁶⁰ Status epilepticus reported with concomitant phenelzine use² ³ ¹⁶¹	Concomitant use contraindicated¹ ^c Allow at least 14 days to elapse when switching to or from these drugs¹ ^c
Methylphenidate	Possible increased plasma clomipramine concentrations¹ ¹⁵⁹
Oral contraceptives	No evidence of interference with clomipramine therapeutic effects¹⁵⁹
Phenytoin	Possible decreased plasma clomipramine concentrations¹ ¹⁵⁹
SSRIs (e.g., fluoxetine, fluvoxamine)	Possible serotonin syndrome^c Potential decreased clomipramine metabolism and increased plasma concentrations^a ^c Possible seizures with concomitant fluoxetine use¹⁷⁰ Severalfold elevation of plasma clomipramine concentration with concomitant fluvoxamine use¹⁷¹	Use with caution;^c monitor for TCA toxicity^a Allow at least 5 weeks to elapse when switching from fluoxetine^a ^c
Smoking	Possible decreased plasma clomipramine concentrations¹ ² ⁴¹ ⁵⁵ ⁶⁰
Sympathomimetic agents (e.g., amphetamines, epinephrine, isoproterenol, norepinephrine, phenylephrine)	Increased vasopressor, cardiac effects^c	Use with caution; dosage adjustment may be required^c
Thyroid agents (e.g., levothyroxine, liothyronine)	May accelerate the onset of therapeutic effects of TCA^c Possible cardiac arrhythmias^c	Use with caution^c
Valproic acid	Possible elevated serum clomipramine concentrations; may precipitate seizures in predisposed individuals²⁹⁸
Warfarin	Possible altered protein binding of clomipramine or warfarin¹ ²	Monitor for adverse effects¹ ²

clomiPRAMINE Pharmacokinetics

Absorption

Bioavailability

Well absorbed following oral administration,² ³ ⁴ ⁵ ¹⁰ ⁵⁵ with peak plasma concentrations usually attained within 2–6 hours (mean: 4.7 hours).¹ ¹⁰ ¹¹ ¹² ²⁵ ²⁹

Oral bioavailability is about 50% because of extensive first-pass metabolism.¹ ² ²⁵ ⁵⁵

Onset

Therapeutic response in OCD generally occurs within 2–6 weeks, with maximal effects after 3–4 months.³³ ⁶⁶ ⁹⁹ ¹⁰³

Food

Food does not appear to substantially affect bioavailability from capsules.¹ ²⁹

Special Populations

In geriatric patients, plasma concentrations of clomipramine and its major active metabolite (desmethylclomipramine) are substantially higher than those in younger adults (18–40 years of age).¹ ⁴¹ ⁶⁰

In children <15 years of age, plasma concentration-dose ratios of clomipramine are substantially lower than those of adults.¹ ⁴³

In smokers, steady-state plasma clomipramine concentrations are substantially lower than in nonsmokers;¹ ⁴¹ ⁵⁵ ⁶⁰ smoking appears to have less effect on plasma concentrations of desmethylclomipramine.⁶⁰

Distribution

Extent

Clomipramine and desmethylclomipramine widely distributed in body tissues, with moderate to high concentrations occurring in organs such as the lungs, adrenals, kidneys, heart, and brain.¹ ³ ⁵ ¹⁰ ⁵³

Crosses the blood-brain barrier; desmethylclomipramine concentration in CSF is about 2.6 times higher than in plasma.¹

Crosses the placenta and distributes into milk.¹ ⁴ ²² ⁵⁵ ⁶⁰ ⁶² ⁷¹

Plasma Protein Binding

Approximately 97–98%, principally to albumin and possibly to α₁-acid glycoprotein (α₁-AGP).¹ ² ⁴ ²⁹ ⁵⁵ ⁵⁶

Elimination

Metabolism

Extensively metabolized to active metabolites¹ ² ³ ⁴ ⁵ ¹⁹ ²⁰ ⁵⁵ ⁶¹ ⁷² ⁷³ by various CYP isoenzymes (e.g., CYP1A2,³⁴⁶ CYP2C,⁷³ CYP2D6,⁷² ⁷³ CYP3A4).^c

Exhibits nonlinear pharmacokinetics at dosages >150 mg daily.¹ ⁸ Metabolism of clomipramine and desmethylclomipramine may be capacity limited (saturable).¹ ⁸ ⁵⁵

Elimination Route

Clomipramine and metabolites excreted in urine and in feces (via biliary elimination).¹ ⁴ ⁵ ¹¹ ²¹ ²⁹ ⁵⁵ ⁷³

Half-life

Elimination half-lives of clomipramine and desmethylclomipramine are approximately 32 hours (range: 19–37 hours) and 69 hours (range: 54–77 hours), respectively, after a 150-mg oral dose.¹ ²

Elimination half-lives may be considerably prolonged at dosages near upper limit of recommended dosage range (i.e., 200–250 mg daily).¹ ⁸

Special Populations

Effects of renal and hepatic impairment on the disposition of clomipramine have not been fully elucidated.¹ ⁶⁰

Hemodialysis, peritoneal dialysis, forced diuresis, and/or exchange transfusion are unlikely to remove clomipramine and desmethylclomipramine substantially because of the drug’s rapid distribution into body tissues.¹

Stability

Storage

Oral

Capsules

Tightly closed container at ≤30°C.¹ Protect from moisture.¹

Actions

Mechanism of action in the management of OCD unknown but may involve inhibition of reuptake of serotonin.¹ ² ³ ²¹³ ²¹⁴ ²²⁰
Desmethylclomipramine inhibits norepinephrine reuptake;² ³ ⁴ ⁴⁸ ²¹² ²¹³ ²¹⁴ ²²⁰ ²²¹ ²³⁵ therefore, clomipramine also shares pharmacologic profile of other tricyclic antidepressants.²³⁵ ²³⁸
Exhibits marked anticholinergic activity, which may account for ³ ⁴ ²⁸⁸ ²⁸⁹ sedation,¹ ⁶⁵ ²³⁸ ²⁴² adverse cardiovascular effects,¹ ² ¹⁹³ ²²² ²³⁵ ³³⁹ and reduced seizure threshold (particularly at relatively high dosages).¹ ²¹⁰

Advice to Patients

Risk of suicidality; importance of patients, family, and caregivers being alert to and immediately reporting emergence of suicidality, worsening depression, or unusual changes in behavior, especially during the first few months of therapy or during periods of dosage adjustment.^d ^e ^f FDA recommends providing written patient information (medication guide) explaining risks of suicidality each time the drug is dispensed.^d ^e ^f
Importance of informing patients about the risk of seizures associated with the drug.¹
Importance of discussing with patients the risk of serious injury to themselves or others resulting from sudden loss of consciousness (e.g., because of seizures) while engaged in certain complex and hazardous activities (e.g., operation of complex machinery, driving a motor vehicle, swimming, climbing).¹
Importance of cautioning patients about the use of alcohol, barbiturates, or other CNS depressants (see Interactions).¹ ²⁴³
Importance of informing male patients about the relatively high incidence of sexual dysfunction associated with the drug.¹ ³ ¹⁸⁰
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.¹
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.¹
Importance of informing patients of other important precautionary information.¹ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

clomiPRAMINE Hydrochloride
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	25 mg*	Anafranil (with parabens)	Mallinckrodt
			clomiPRAMINE Hydrochloride Capsules	Mylan
		50 mg*	Anafranil (with parabens)	Mallinckrodt
			clomiPRAMINE Hydrochloride Capsules	Mylan
		75 mg*	Anafranil (with parabens)	Mallinckrodt
			clomiPRAMINE Hydrochloride Capsules	Mylan

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Novartis Pharmaceuticals. Anafranil (clomipramine hydrochloride) capsules prescribing information (dated 1998 Apr). In: Physician’s desk reference. 54th ed. Montvale, NJ: Medical Economics Company Inc; 2000:1988-92.

2. Peters MD II, Davis SK, Austin LS. Clomipramine: an antiobsessional tricyclic antidepressant. Clin Pharm. 1990; 9:165-78. http://www.ncbi.nlm.nih.gov/pubmed/2180623?dopt=AbstractPlus

3. Kelly MW, Myers CW. Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. DICP. 1990; 24:739-44. http://www.ncbi.nlm.nih.gov/pubmed/2197816?dopt=AbstractPlus

4. McTavish D, Benfield P. Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs. 1990; 39:136-53. http://www.ncbi.nlm.nih.gov/pubmed/2178909?dopt=AbstractPlus

5. Faigle JW, Dieterle W. The metabolism and pharmacokinetics of clomipramine (Anafranil). J Int Med Res. 1973; 1:281-90.

6. Luscombe DK, Wright J, Stern RS et al. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis. Postgrad Med J. 1980; 56(Suppl 1):140-3. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2425517&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7393825?dopt=AbstractPlus

7. Luscombe DK, Marks IM. Pharmacokinetic studies in obsessional patients. J Int Med Res. 1977; 5(Suppl 5):91-6. http://www.ncbi.nlm.nih.gov/pubmed/598610?dopt=AbstractPlus

8. Kuss HJ, Jungkunz G. Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients. Prog Neuropschopharmacol Biol Psychiatry. 1986; 10:739-48.

9. Burch JE, Shaw DM, Michalakeas A et al. Time course of plasma drug levels during once-daily oral administration of clomipramine. Psychopharmacology. 1982; 77:344-7. http://www.ncbi.nlm.nih.gov/pubmed/6813895?dopt=AbstractPlus

10. Luscombe DK. Pharmacokinetics of clomipramine. Br J Clin Pract. 1979; 33(Suppl 3):35-50.

11. Jones RB, Luscombe DK. Single dose studies with clomipramine in normal subjects. Postgrad Med J. 1976; 52(Suppl 3):62-7. http://www.ncbi.nlm.nih.gov/pubmed/959092?dopt=AbstractPlus

12. Jones RB, Luscombe DK. Plasma levels of clomipramine and its N- desmethyl metabolite following oral administration of clomipramine in man. Br J Pharmacol. 1976 Jul;57(3):430P.

13. Gringras M, Luscombe DK, Jones RB et al. A clinical trial of a 50 mg formulation of clomipramine (Anafranil) with steady-state plasma level measurements. J Int Med Res. 1977; 5(Suppl 1):119-24. http://www.ncbi.nlm.nih.gov/pubmed/863081?dopt=AbstractPlus

14. Jones RB, Luscombe DK. Plasma level studies with clomipramine (Anafranil). J Int Med Res. 1977; 5(Suppl 1):89-107.

15. Alfredsson G, Wiesel FA, Fyro B et al. Mass fragmentographic analysis of clomipramine and its mono-demthylated metabolite in human plasma. Psychopharmacology. 1977; 52:25-30. http://www.ncbi.nlm.nih.gov/pubmed/403553?dopt=AbstractPlus

16. Stern RS, Cobb JP, Marks IM et al. A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis. Postgrad Med J. 1977; 53(Suppl 4):97-103. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2496633&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/341110?dopt=AbstractPlus

17. Carnis G, Godbillon J, Metayer JP. Determination of clomipramine and desmethyl-clomipramine in plasma or urine by the double-radioisotope derivative technique. Clin Chem. 1976; 22:817-23. http://www.ncbi.nlm.nih.gov/pubmed/6163?dopt=AbstractPlus

18. Broadhurst AD, James HD, Della Corte L et al. Clomipramine plasma level and clinical response. Postgrad Med J. 1977; 53(Suppl 4):139-45. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2496476&blobtype=pdf

19. Linnoila M, Insel T, Kilts C et al. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clin Pharmacol Ther. 1982; 32:208-11. http://www.ncbi.nlm.nih.gov/pubmed/7094507?dopt=AbstractPlus

20. Nagy A, Johansson R. The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology. 1977; 54:125-31. http://www.ncbi.nlm.nih.gov/pubmed/412206?dopt=AbstractPlus

21. Dubois JP, Kung W, Theobald W et al. Measurement of clomipramine, N-desmethylclomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine. Clin Chem. 1976; 22:892-7. http://www.ncbi.nlm.nih.gov/pubmed/1277478?dopt=AbstractPlus

22. Takemura M, Toshida S, Fuchino K. Excretion of clomipramine and desmethylclomipramine in human breast milk. Seishin Igaku. 1982; 24: 749- 53.

23. Vandel B, Vandel S, Jounet JM et al. Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response. Eur J Clin Pharmacol. 1982; 22:15-20. http://www.ncbi.nlm.nih.gov/pubmed/7094971?dopt=AbstractPlus

24. Moody JP. The biological availability of clomipramine (Anafranil). J Int Med Res. 1973; 1:325-30.

25. Evans LEJ, Bett JHN, Cox JR et al. The bioavailability of oral and parenteral chlorimipramine (Anafranil). Prog Neuro-pychopharmacol Biol Psychiatry. 1980; 4:293-302.

26. Bertilsson L, Braithwaite R, Tybring G et al. Techniques for plasma protein binding of demethylchlorimipramine. Clin Pharmacol Ther. 1979; 26:265-71. http://www.ncbi.nlm.nih.gov/pubmed/455895?dopt=AbstractPlus

27. Jones RB, Luscombe DK. Plasma concentrations of clomipramine and its N-desmethyl metabolite in depressive patients following treatment with various dosage regimes of clomipramine. Postgrad Med Journal. 1977; 53(Suppl 4):63-76.

28. Mellstrom B, Tybring G. Ion-pair liquid chromatography of steady-state plasma levels of chlorimipramine and demethylchlorimipramine. Journal of Chromatography. 1977; 143:597-605. http://www.ncbi.nlm.nih.gov/pubmed/914950?dopt=AbstractPlus

29. Jermain DM, Crismon ML. Pharmacotherapy of obsessive-compulsive disorder. Pharmacotherapy. 1990; 10:175-98. http://www.ncbi.nlm.nih.gov/pubmed/2196535?dopt=AbstractPlus

30. Stern RS, Marks IM, Mawson D et al. Clomipramine and exposure for compulsive rituals: II. plasma levels, side effects and outcome. Br J Psychiatry. 1980; 136:161-6. http://www.ncbi.nlm.nih.gov/pubmed/7370482?dopt=AbstractPlus

31. Stern RS, Marks IM, Wright J et al. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis. Postgrad Med J. 1980; 56(Suppl 1):134-9. http://www.ncbi.nlm.nih.gov/pubmed/7393824?dopt=AbstractPlus

32. Kasvikis Y, Marks IM. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations betweeen dose, plasma levels, outcome and side effects. Psychopharmacology. 1988; 95:113-8. http://www.ncbi.nlm.nih.gov/pubmed/3133689?dopt=AbstractPlus

33. Insel TR, Murphy DL, Cohen RM et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983; 40:605-12. http://www.ncbi.nlm.nih.gov/pubmed/6342562?dopt=AbstractPlus

34. Thoren P, Asberg M, Bertilsson L et al. Clomipramine treatment of obsessive-compulsive disorder: II. biochemical aspects. Arch Gen Psychiatry. 1980; 37:1289-94. http://www.ncbi.nlm.nih.gov/pubmed/6159865?dopt=AbstractPlus

35. Flament MF, Rapoport JL, Berg CJ et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry. 1985; 42:977-83. http://www.ncbi.nlm.nih.gov/pubmed/3899048?dopt=AbstractPlus

36. Mavissakalian MR, Jones B, Olson S et al. Clomipramine in obsessive- compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol. 1990; 10:261-8. http://www.ncbi.nlm.nih.gov/pubmed/2286699?dopt=AbstractPlus

37. Mavrissakalian M, Jones B, Olson S et al. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder. Psychopharmacol Bull. 1990; 26:119-22. http://www.ncbi.nlm.nih.gov/pubmed/2371366?dopt=AbstractPlus

38. Della Corte L, Broadhurst AD, Sgaragli GP et al. Clinical response and tricyclic plasma levels during treatment with clomipramine. Br J Psychiatry. 1979; 134:390-400. http://www.ncbi.nlm.nih.gov/pubmed/444789?dopt=AbstractPlus

39. Dutt JE. On the clinical response/plasma level relationship for clomipramine. Br J Psychiatry. 1982; 140:105. http://www.ncbi.nlm.nih.gov/pubmed/7059735?dopt=AbstractPlus

40. Dawling S, Braithwaite RA, McAuley R et al. Single oral dose pharmacokinetics of clomipramine in depressed patients. Postgrad Med J. 1980; 56(Suppl 1):115-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2425519&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7393820?dopt=AbstractPlus

41. John VA, Luscombe DK, Kemp H. Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics of clomipramine and its desmethyl metabolite during chronic dosing. J Int Med Res. 1980; 8(Suppl 3):88-95. http://www.ncbi.nlm.nih.gov/pubmed/7202824?dopt=AbstractPlus

42. Luscombe DK, John V. Influence of age, cigarette smoking and the oral contraceptive on plasma concentrations of clomipramine. Postgrad Med J. 1980; 56(Suppl 10:99-102.

43. Dugas M, Zarifian E, Leheuzey MF et al. Preliminary observations of the significance of monitoring tricyclic antidepressant plasma levels in the pediatric patient. Therapeutic Drug Monitoring. 1980; 2:307-14. http://www.ncbi.nlm.nih.gov/pubmed/7222184?dopt=AbstractPlus

44. Miller P, Luscombe DK, Jones RB et al. Relationships between clinical response, plasma levels and side-effects of clomipramine (Anafranil) in general practitioner trials. J Int Med Res. 1977; 5(Suppl 1):108-18. http://www.ncbi.nlm.nih.gov/pubmed/863079?dopt=AbstractPlus

45. Montgomery SA, McAuley R, Montgomery DB et al. Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients. Postgrad Med J. 1980; 56(Suppl 1):130-3. http://www.ncbi.nlm.nih.gov/pubmed/7393823?dopt=AbstractPlus

46. Moyes ICA, Ray RL, Moyes RB. Plasma levels and clinical improvement - a comparative study of clomipramine and amitriptyline in depression. Postgrad Med J. 1980; 56(Suppl 1):127-9. http://www.ncbi.nlm.nih.gov/pubmed/7393822?dopt=AbstractPlus

47. Reisby N, Gram LF, Bech P et al. Clomipramine: plasma levels and clinical effects. Commun Psychopharmacol. 1979; 3:341-51. http://www.ncbi.nlm.nih.gov/pubmed/548213?dopt=AbstractPlus

48. Traskman L, Asberg M, Bertilsson L et al. Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin Pharmacol Ther. 1979; 26:600-10. http://www.ncbi.nlm.nih.gov/pubmed/498703?dopt=AbstractPlus

49. Mulgirigama LD, Pare CMB, Turner P et al. Clinical response in depressed patients in relation to plasma levels of tricyclic antidepressants and tyramine pressor response. Postgrad Med J. 1977; 53(Suppl 4):155-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2496471&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/341104?dopt=AbstractPlus

50. Faravelli C, Ballerini A, Broadhurst AD et al. Relevance of plasma levels during clomipramine treatment of primary depression. J Affect Disord. 1982; 4:163-5. http://www.ncbi.nlm.nih.gov/pubmed/6213693?dopt=AbstractPlus

51. Faravelli C, Ballerini A, Ambonetti A et al. Plasma levels and clinical response during treatment with clomipramine. J Affect Disord. 1984; 6:95-107. http://www.ncbi.nlm.nih.gov/pubmed/6231334?dopt=AbstractPlus

52. Montastruc JL, Tran MA, Blanc M et al. Measurement of plasma levels of clomipramine in the treatment of chronic pain. Clin Neuropharmacol. 1985; 8:78-82. http://www.ncbi.nlm.nih.gov/pubmed/3978652?dopt=AbstractPlus

53. Pounder DJ, Jones GR. Post-mortem drug redistribution - a toxicological nightmare. Forensic Sci Int. 1990; 45:253-63. http://www.ncbi.nlm.nih.gov/pubmed/2361648?dopt=AbstractPlus

54. Hullin RP. Variation in plasma concentrations of clomipramine and desmethylclomipramine during clomipramine therapy. Postgrad Med J. 1980; 56(Suppl 1):117-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2425509&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7190279?dopt=AbstractPlus

55. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet. 1991; 20:447-62. http://www.ncbi.nlm.nih.gov/pubmed/2044329?dopt=AbstractPlus

56. Martensson E, Axelsson R, Nyberg G et al. Pharmacokinetic properties of the antidepressant drugs amitriptyline, clomipramine, and imipramine: a clinical study. Curr Ther Res. 1984; 36:228-38.

57. Balant-Gorgia AE, Balant LP, Genet C et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol. 1986; 31:449-55. http://www.ncbi.nlm.nih.gov/pubmed/2880723?dopt=AbstractPlus

58. Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit. 1989; 11:415-20. http://www.ncbi.nlm.nih.gov/pubmed/2741190?dopt=AbstractPlus

59. Balant-Gorgia AE, Balant L, Zysset T. High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer. Eur J Clin Pharmacol. 1987; 32:101-2. http://www.ncbi.nlm.nih.gov/pubmed/3582462?dopt=AbstractPlus

60. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet. 1994; 27:307-330. http://www.ncbi.nlm.nih.gov/pubmed/7834966?dopt=AbstractPlus

61. Nielsen KK, Brosen K. High-performance liquid chromatography of clomipramine and metabolites in human plasma and urine. Ther Drug Monit. 1993; 15:122-8. http://www.ncbi.nlm.nih.gov/pubmed/8503140?dopt=AbstractPlus

62. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry. 1995; 56:17-20. http://www.ncbi.nlm.nih.gov/pubmed/7836334?dopt=AbstractPlus

63. Gex-Fabry M, Balant-Gorgia AE, Balant LP et al. Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet. 1990; 19:241-55. http://www.ncbi.nlm.nih.gov/pubmed/2394063?dopt=AbstractPlus

64. Balant-Gorgia AE, Gay M, Gex-Fabry M et al. Persistent impairment of clomipramine demethylation in recently detoxified alcoholic patients. Ther Drug Monit. 1992; 14:119-24. http://www.ncbi.nlm.nih.gov/pubmed/1585395?dopt=AbstractPlus

65. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991; 48:730-8. http://www.ncbi.nlm.nih.gov/pubmed/1883256?dopt=AbstractPlus

66. DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatric Annals. 1989; 19:97- 101.

67. DeVeaugh-Geiss J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull. 1989; 25:36-40. http://www.ncbi.nlm.nih.gov/pubmed/2672070?dopt=AbstractPlus

68. Pigott TA, Pato MT, Bernstein SE et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch Gen Psychiatry. 1990; 47:926-32. http://www.ncbi.nlm.nih.gov/pubmed/2222131?dopt=AbstractPlus

69. Greist JH, Jefferson JW, Kobak KA et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry. 1995; 52:53-60. http://www.ncbi.nlm.nih.gov/pubmed/7811162?dopt=AbstractPlus

70. Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive- compulsive disorder. Biol Psychiatry. 1990; 28:401-14. http://www.ncbi.nlm.nih.gov/pubmed/2207219?dopt=AbstractPlus

71. Schimmell MS, Katz EZ, Shaag Y et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol. 1991; 29:479-84. http://www.ncbi.nlm.nih.gov/pubmed/1749054?dopt=AbstractPlus

72. Nielsen KK, Brosen K, Gram LF et al. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1992; 43:405-11. http://www.ncbi.nlm.nih.gov/pubmed/1451721?dopt=AbstractPlus

73. Nielsen KK, Brosen K, Hansen MGJ et al. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. . Clin Pharmacol Ther. 1994; 55:518-27.

74. Nielsen KK, Brosen K, Hansen MGJ et al. Gluconidation clearance of 8- hydroxyclomipramine in relation to sparteine and mephenytoin phenotype. Eur J Clin Pharmacol. 1994; 47:209-10. http://www.ncbi.nlm.nih.gov/pubmed/7859811?dopt=AbstractPlus

75. Allen JJ, Rack PH, Vaddadi KS. Differences in the effects of clomipramine on English and Asian volunteers. prelimminary report on a pilot study. Postgrad Med J. 1977; 53(Suppl 4):79-86. http://www.ncbi.nlm.nih.gov/pubmed/341109?dopt=AbstractPlus

76. Shimoda K, Minowada T, Noguchi T et al. Interindividual variations of desmethylation and hydroxylation of clomipramine in an oriental psychiatric population. J Clin Psychopharmacol. 1993; 13:181-8. http://www.ncbi.nlm.nih.gov/pubmed/8354734?dopt=AbstractPlus

77. Ackerman DL, Greenland S, Bystritsky A et al. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol. 1994; 14:247- 54. http://www.ncbi.nlm.nih.gov/pubmed/7962680?dopt=AbstractPlus

78. Pato MT, Zohar-Kadouch R, Zohar J et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988; 145:1521-5. http://www.ncbi.nlm.nih.gov/pubmed/3057923?dopt=AbstractPlus

79. Katz RJ, DeVeaugh-Geiss J. The antiobsessional effects of clomipramine do not require concomitant affective disorder. Psychiatry Res. 1990; 31:121-9. http://www.ncbi.nlm.nih.gov/pubmed/2183254?dopt=AbstractPlus

80. Marks IM, Stern RS, Mawson D et al. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry. 1980; 136:1-25. http://www.ncbi.nlm.nih.gov/pubmed/6986939?dopt=AbstractPlus

81. Thoren P, Asberg M, Cronholm B et al. Clomipramine treatment of obsessive-compulsive disorder: I. a controlled clinical trial. Arch Gen Psychiatry. 1980; 37:1281-5. http://www.ncbi.nlm.nih.gov/pubmed/7436690?dopt=AbstractPlus

82. Leonard HL, Swedo SE, Lenane MC et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991; 48:922-7. http://www.ncbi.nlm.nih.gov/pubmed/1929762?dopt=AbstractPlus

83. Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry. 1994; 55:301-5. http://www.ncbi.nlm.nih.gov/pubmed/8071291?dopt=AbstractPlus

84. Marks IM, Lelliott P, Basoglu M et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry. 1988; 152:522-34. http://www.ncbi.nlm.nih.gov/pubmed/3167404?dopt=AbstractPlus

85. Berman I, Sapers BL, Chang HHJ et al. Treatment of obsessive- compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol. 1995; 15:206-10. http://www.ncbi.nlm.nih.gov/pubmed/7635998?dopt=AbstractPlus

86. Tejera CA, Mayerhoff DI, Ramos-Lorenzi J. Clomipramine for obsessive-compulsive symptoms in schizophrenia. J Clin Psychopharmacol. 1993; 13:290-1. http://www.ncbi.nlm.nih.gov/pubmed/8376620?dopt=AbstractPlus

87. O’sullivan G, Noshirvani H, Marks I et al. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. J Clin Psychiatry. 1991; 52:150-5. http://www.ncbi.nlm.nih.gov/pubmed/2016246?dopt=AbstractPlus

88. Yaryura-Tobias JA, Neziroglu F, Bergman L. Chlorimipramine, for obsessive-compulsive neurosis: an organic approach. Curr Ther Res. 1976; 20:541-8.

89. Greist JH, Jefferson JW, Rosenfeld R et al. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. J Clin Psychiatry. 1990; 51:292-7. http://www.ncbi.nlm.nih.gov/pubmed/2195006?dopt=AbstractPlus

90. Lee S. Clomipramine in obsessive compulsive disorder. J Clin Psychiatry. 1991; 52:183-4. http://www.ncbi.nlm.nih.gov/pubmed/2016256?dopt=AbstractPlus

91. Greist JH, Jefferson JW. Drs. Greist and Jefferson reply. J Clin Psychiatry. 1991; 52:184-5.

92. Jenike MA, Baer L, Summergrad P et al. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry. 1989; 146:1328-30. http://www.ncbi.nlm.nih.gov/pubmed/2675643?dopt=AbstractPlus

93. Yaryura-Tobias JA. Chlorimipramine in Gilles de la Tourette’s disease. Am J Psychiatry. 1975; 132:1221. http://www.ncbi.nlm.nih.gov/pubmed/1058644?dopt=AbstractPlus

94. Ratzoni G, Hermesh H, Brandt N et al. Clomipramine efficacy for tics, obsessions, and compulsions in Tourette’s syndrome and obsessive-compulsive disorder: a case study. Biol Psychiatry. 1990; 27:95-8. http://www.ncbi.nlm.nih.gov/pubmed/2297555?dopt=AbstractPlus

95. Caine ED, Polinsky RJ, Ebert MH et al. Trial of chlorimipramine and desipramine for Gilles de la Tourette syndrome. Ann Neurol. 1979; 5:305- 6. http://www.ncbi.nlm.nih.gov/pubmed/375806?dopt=AbstractPlus

96. Koran LM, McElroy SL, Davidson JRT et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol. 1996; 16:121-9. http://www.ncbi.nlm.nih.gov/pubmed/8690827?dopt=AbstractPlus

97. Rasmussen SA. Lithium and tryptophan augmentation in clomipramine- resistant obsessive-compulsive disorder. Am J Psychiatry. 1984; 141:1283- 5. http://www.ncbi.nlm.nih.gov/pubmed/6435460?dopt=AbstractPlus

98. Feder R. Lithium augmentation of clomipramine. J Clin Psychiatry. 1988; 49:458. http://www.ncbi.nlm.nih.gov/pubmed/3141389?dopt=AbstractPlus

99. Pigott TA, Pato MT, L’Heureux F et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clompramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1991; 11:242-8. http://www.ncbi.nlm.nih.gov/pubmed/1918422?dopt=AbstractPlus

100. Tamimi RR, Mavissakalian MR. Are effective antiobsessional drugs interchangeable? Arch Gen Psychiatry. 1991; 48:857-8. Letter.

101. Pigott TA, Murphy DL. Are effective antiobsessional drugs interchangeable? Arch Gen Psychiatry. 1991; 48:858-9. Letter.

102. Bark N, Lindenmayer JP. Ineffectiveness of clomipramine for obsessive-compulsive symptoms in a patient with schizophrenia. Am J Psychiatry. 1992; 149:136-7. http://www.ncbi.nlm.nih.gov/pubmed/1728163?dopt=AbstractPlus

103. Stroebel CF, Szarek BL, Glueck BC. Use of clomipramine in treatment of obsessive-compulsive symptomatology. J Clin Psychopharmacol. 1984; 4:98-100. http://www.ncbi.nlm.nih.gov/pubmed/6707247?dopt=AbstractPlus

104. Gloger S, Grunhaus L, Gladic D et al. Panic attacks and agoraphobia: low dose clomipramine treatment. J Clin Psychopharmacol. 1989; 9:28-32. http://www.ncbi.nlm.nih.gov/pubmed/2651491?dopt=AbstractPlus

105. Gloger S, Grunhaus L, Birmacher B et al. Treatment of spontaneous panic attacks with chlomipramine. Am J Psychiatry. 1981; 138:1215-7. http://www.ncbi.nlm.nih.gov/pubmed/7270727?dopt=AbstractPlus

106. Grunhaus L, Gloger S, Birmacher B. Clomipramine treatment for panic attacks in patients with mitral valve prolapse. J Clin Psychiatry. 1984; 45:25-7. http://www.ncbi.nlm.nih.gov/pubmed/6363396?dopt=AbstractPlus

107. Kahn RS, Westenberg HGM, Verhoeven WMA et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol. 1987; 2:33-45. http://www.ncbi.nlm.nih.gov/pubmed/3312397?dopt=AbstractPlus

108. den Boer JA, Westenberg HGM, Kamerbeek WDJ et al. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol. 1987; 2:21-32. http://www.ncbi.nlm.nih.gov/pubmed/3117876?dopt=AbstractPlus

109. Cassano GB, Petracca A, Perugi G et al. Clomipramine for panic disorder: I. the first 10 weeks of a long-term comparison with imipramine. J Affect Disord. 1988; 14:123-7. http://www.ncbi.nlm.nih.gov/pubmed/2966825?dopt=AbstractPlus

110. Johnston DG, Troyer IE, Whitsett SF. Clomipramine treatment of agoraphobic women: an eight-week controlled trial. Arch Gen Psychiatry. 1988; 453-9. (IDIS 241074)

111. Langohr HD, Stohr M, Petruch F. An open and double-blind cross-over study on the efficacy of clomipramine (Anafranil) in patients with painful mono- and polyneuropathies. Eur Neurol. 1982; 21:309-17. http://www.ncbi.nlm.nih.gov/pubmed/6126361?dopt=AbstractPlus

112. Ganvir P, Beaumont G, Seldrup J. A comparative trial of clomipramine and placebo as adjunctive therapy in arthralgia. J Int Med Res. 1980; 8(Suppl 3):60-6. http://www.ncbi.nlm.nih.gov/pubmed/7009255?dopt=AbstractPlus

113. Gerson GR, Jones RB, Luscombe DK. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. Postgrad Med J. 1977; 53(Suppl 4):104-9. http://www.ncbi.nlm.nih.gov/pubmed/304576?dopt=AbstractPlus

114. Carasso RL, Yehuda S, Streifler M. Clomipramine and amitriptyline in the treatment of severe pain. Int J Neurosci. 1979; 9:191-4. http://www.ncbi.nlm.nih.gov/pubmed/489262?dopt=AbstractPlus

115. Eberhard G, von Knorring L, Nilsson HL et al. A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes. Neuropsychobiology. 1988; 19:25-34. http://www.ncbi.nlm.nih.gov/pubmed/3054623?dopt=AbstractPlus

116. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992; 12:251-61. http://www.ncbi.nlm.nih.gov/pubmed/1527228?dopt=AbstractPlus

117. Hoffart A, Due-Madsen J, Lande B et al. Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry/. 1993; 54:481-7.

118. Magni G. The use of antidepressants in the treatment of chronic pain: a review of the current evidence. Drugs. 1991; 42:730-48. http://www.ncbi.nlm.nih.gov/pubmed/1723371?dopt=AbstractPlus

119. Langohr HD, Gerber WD, Koletzky E et al. Clomipramine and metaprolol in migraine prophylaxis—a double-blind crossover study. Headache. 1985; 25:107-13. http://www.ncbi.nlm.nih.gov/pubmed/3886599?dopt=AbstractPlus

120. Noone JF. Clomipramine in the prevention of migraine. J Int Med Res. 1980; 8(Suppl 3):49-52. http://www.ncbi.nlm.nih.gov/pubmed/7009254?dopt=AbstractPlus

121. Loldrup D, Langemark M, Hansen HJ et al. Clomipramine and mianserin in chronic idiopathic pain syndrome: a placebo controlled study. Psychopharmacology. 1989; 99:1-7. http://www.ncbi.nlm.nih.gov/pubmed/2506594?dopt=AbstractPlus

122. Langemark M, Lodrup D, Bech P et al. Clomipramine and mianserin in the treatment of chronic tension headache. a double-blind, controlled study. Headache. 1990; 30:118-21. http://www.ncbi.nlm.nih.gov/pubmed/2182566?dopt=AbstractPlus

123. Rummans TA. Nonopioid agents for treatment of acute and subacute pain. Mayo Clin Proc. 1994; 69:481-90. http://www.ncbi.nlm.nih.gov/pubmed/8080514?dopt=AbstractPlus

124. Panerai AE, Monza G, Movilia P et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand. 1990; 82:34-8. http://www.ncbi.nlm.nih.gov/pubmed/2239134?dopt=AbstractPlus

125. Sindrup SH, Gram LF, Skjold T et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. a double-blind cross- over study. Br J Clin Pharmacol. 1990; 30:683-91. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1368167&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2271367?dopt=AbstractPlus

126. Calissi PT, Jaber LA. Peripheral diabetic neuropathy: current concepts in treatment. Ann Pharmacother. 1995; 29:769-77. http://www.ncbi.nlm.nih.gov/pubmed/8520095?dopt=AbstractPlus

127. Wright JM. Review of the symptomatic treatment of diabetic neuropathy. Pharmacotherapy. 1994; 14:689-97. http://www.ncbi.nlm.nih.gov/pubmed/7885972?dopt=AbstractPlus

128. Eaton H. Clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res. 1973; 1:432-4.

129. Goodman RE. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res. 1980; 8(Suppl 3):53-9. http://www.ncbi.nlm.nih.gov/pubmed/7193614?dopt=AbstractPlus

130. Girgis SM, El-Haggar S, El-Hermouzy S. A double-blind trial of clomipramine in premature ejaculation. Andrologia. 1982; 14:364-8. http://www.ncbi.nlm.nih.gov/pubmed/6751156?dopt=AbstractPlus

131. Althof SE, Levine SB, Corty EW et al. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry. 1995; 56:402-7. http://www.ncbi.nlm.nih.gov/pubmed/7665538?dopt=AbstractPlus

132. Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol. 1975; 32:653-6. http://www.ncbi.nlm.nih.gov/pubmed/170899?dopt=AbstractPlus

133. Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 1980; 43:171-4. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=490494&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6766990?dopt=AbstractPlus

134. Gilman JT, Tuchman RF. Autism and associated behavioral disorders: pharmacotherapeutic intervention. Ann Pharmacother. 1995; 29:47-56. http://www.ncbi.nlm.nih.gov/pubmed/7711345?dopt=AbstractPlus

135. Gordon CT, Rapoport JL, Hamburger SD et al. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry. 1992; 149:363-6. http://www.ncbi.nlm.nih.gov/pubmed/1536276?dopt=AbstractPlus

136. Swedo SE, Leonard HL, Rapoport JL et al. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989; 321:497-501. http://www.ncbi.nlm.nih.gov/pubmed/2761586?dopt=AbstractPlus

137. Swedo SE, Lenane MC, Leonard HL. Long-term treatment of trichotillomania (hair pulling). N Engl J Med. 1993; 329:141-2. http://www.ncbi.nlm.nih.gov/pubmed/8510704?dopt=AbstractPlus

138. Black DW, Blum N. Trichotillomania treated with clomipramine and a topical steroid. Am J Psychiatry. 1992; 149:842-3. http://www.ncbi.nlm.nih.gov/pubmed/1303620?dopt=AbstractPlus

139. Gupta S, Freimer M. Trichotillomania, clomipramine, topical steroids. Am J Psychiatry. 1993; 150:524. http://www.ncbi.nlm.nih.gov/pubmed/8434676?dopt=AbstractPlus

140. Pollard CA, Ibe IO, Krojanker DN et al. Clomipramine treatment of trichotillomania: a floow-up report on four cases. J Clin Psychiatry. 1991; 52:128-30. http://www.ncbi.nlm.nih.gov/pubmed/2005076?dopt=AbstractPlus

141. Gordon CT, State RC, Nelson JE et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993; 50:441-7. http://www.ncbi.nlm.nih.gov/pubmed/8498878?dopt=AbstractPlus

142. Leonard HL, Lenane MC, Swedo SE et al. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry. 1991; 48:821-7. http://www.ncbi.nlm.nih.gov/pubmed/1929772?dopt=AbstractPlus

143. Gordon CT, Cotelingam GM, Stager S et al. A double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. J Clin Psychiatry. 1995; 56:238-42. http://www.ncbi.nlm.nih.gov/pubmed/7775365?dopt=AbstractPlus

144. Matthew HJS. The management of self-poisoning due to clomipramine (Anafranil). J Int Med Res. 1973; 1:485-8.

145. Fraser AD, Isner AF, Moss MA. A fatality involving clomipramine. J Forensic Sci. 1986; 31:762-7. http://www.ncbi.nlm.nih.gov/pubmed/2872264?dopt=AbstractPlus

146. Haqqani MT, Gutteridge DR. Two cases of clomipramine hydrochloride (Anafranil) poisoning. Forensic Sci. 1974; 3:83-7. http://www.ncbi.nlm.nih.gov/pubmed/4426550?dopt=AbstractPlus

147. Meatherall RC, Guay DRP, Chalmers JL. A fatal overdose with clomipramine. J Anal Toxicol. 1983; 7:168-71. http://www.ncbi.nlm.nih.gov/pubmed/6632798?dopt=AbstractPlus

148. Diamond BI, Borison RL, Katz R et al. Rebound withdrawal reactions due to clomipramine. Psychopharmcol Bull. 1989; 25:209-12.

149. Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994; 93:137-50. http://www.ncbi.nlm.nih.gov/pubmed/8265310?dopt=AbstractPlus

150. Eidelman AI, Schimmel MS. Drugs and breast milk. Pediatrics. 1995; 95:956-7. http://www.ncbi.nlm.nih.gov/pubmed/7761234?dopt=AbstractPlus

151. Berlin CM Jr. Drugs and breast milk. Pediatrics. 1995; 95:957-8. http://www.ncbi.nlm.nih.gov/pubmed/7761235?dopt=AbstractPlus

152. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ. 1982; 284:1837-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1498765&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6805722?dopt=AbstractPlus

153. Singh S, Gulati S, Narang A et al. Non-narcotic withdrawal syndrome in a neonate due to maternal clomipramine therapy. J Paediatr Child Health. 1990; 26:110. http://www.ncbi.nlm.nih.gov/pubmed/2361068?dopt=AbstractPlus

154. Ostergaard GZ, Pedersen SE. Neonatal effects of maternal clomipamine treatment. Pediatrics. 1982; 69:233-4. http://www.ncbi.nlm.nih.gov/pubmed/7058100?dopt=AbstractPlus

155. van Scheyen JD, van Kammen DP. Clomipramine-induced mania in unipolar depresssion. Arch Gen Psychiatry. 1979; 36:560-5. http://www.ncbi.nlm.nih.gov/pubmed/435016?dopt=AbstractPlus

156. van Kammen DP, van Scheyen JD, Murphy DL. Platelet monoamine oxidase activity and clomipramine-induced mania in unipolar depressed patients. Biol Psychiatry. 1980; 15:565-73. http://www.ncbi.nlm.nih.gov/pubmed/7397287?dopt=AbstractPlus

157. Ansseau M, Reynolds CF III, Kupfer DJ et al. Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. J Clin Psychiatry. 1986; 47:320-1. http://www.ncbi.nlm.nih.gov/pubmed/3011760?dopt=AbstractPlus

158. Ben Musa A, Smith CS. Neonatal effects of maternal clomipramine therapy. Arch Dis Child. 1979; 54:405. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1545555&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/486239?dopt=AbstractPlus

159. Beaumont G. Drug interactions with clomipramine (Anafranil). J Int Med Res. 1973; 1:480-4.

160. Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia. 1987; 42:760-3. http://www.ncbi.nlm.nih.gov/pubmed/3631476?dopt=AbstractPlus

161. Pascual J, Combarros O, Berciano J. Partial status epilepticus following single low dose of clorimipramine in a patient on MAO-inhibitor treatment. Clin Neuropharmacol. 1987; 10:565-7. http://www.ncbi.nlm.nih.gov/pubmed/3427564?dopt=AbstractPlus

162. Souhami RL, Ashton CR, Lee-Potter JP. Agranulocytosis and sytemic candidiasis following clomipramine therapy. Postgrad Med J. 1976; 52:472- 4. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2496401&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/967767?dopt=AbstractPlus

163. Magni G, Urbani A, Silvestro A et al. Clomipramine-induced pancytopenia. J Nerv Ment Dis. 1987; 175:309-10. http://www.ncbi.nlm.nih.gov/pubmed/3572384?dopt=AbstractPlus

164. Gravenor DS, Leclerc JR, Blake G. Tricyclic antidepressant agranulocytosis. Can J Psychiatry. 1986; 31:661. http://www.ncbi.nlm.nih.gov/pubmed/3779595?dopt=AbstractPlus

165. Hunt KA, Resnick MP. Clomipamine-induced agranulocytosis and its treatment with G-CSF. Am J Psychiatry. 1993; 150:522-3. http://www.ncbi.nlm.nih.gov/pubmed/7679557?dopt=AbstractPlus

166. Alderman CP, Atchison MM, McNeece JI. Concurrent agranulocytosis and hepatitis secondary to clomipramine therapy. Br J Psychiatry. 1993; 162:688-9. http://www.ncbi.nlm.nih.gov/pubmed/8149124?dopt=AbstractPlus

167. Roberge RJ, Martin TG, Hodgman M et al. Acute chemical pancreatitis associated with a tricyclic antidepressant (clomipramine) overdose. Clinical Toxicology. 1994; 32:425-9. http://www.ncbi.nlm.nih.gov/pubmed/8057402?dopt=AbstractPlus

168. Hulten BA, Adams R, Askenasi R et al. Predicting severity of tricyclic antidepressant overdose. Clinical Toxicology. 1992; 30:161-70. http://www.ncbi.nlm.nih.gov/pubmed/1588666?dopt=AbstractPlus

169. Bromiker R, Kaplan M. Apparent intrauterine fetal withdrawal from clomipramine hydrochloride. JAMA. 1994; 272:1722-3. http://www.ncbi.nlm.nih.gov/pubmed/7966912?dopt=AbstractPlus

170. Sternbach H. Fluoxetine-clomipramine interaction. J Clin Psychiatry. 1995; 56:171-2. http://www.ncbi.nlm.nih.gov/pubmed/7713858?dopt=AbstractPlus

171. Bertschy G, Vandel S, Vandel B et al. Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol. 1991; 40:119-20. http://www.ncbi.nlm.nih.gov/pubmed/1905641?dopt=AbstractPlus

172. Nirenberg DW, Semprebon M. The central nervous system serotonin syndrome. /Clin Pharmacol Ther. 1993; 53:84-8.

173. Neuvonen PJ, Pohjola-Sintonen S, Tacke U et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993; 342:1419. http://www.ncbi.nlm.nih.gov/pubmed/7901695?dopt=AbstractPlus

174. Kojima H, Terao T, Yoshimura R. Serotonin syndrome during clomipramine and lithium treatment. Am J Psychiatry. 1993; 150:1897. http://www.ncbi.nlm.nih.gov/pubmed/8238650?dopt=AbstractPlus

175. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148:705-13. http://www.ncbi.nlm.nih.gov/pubmed/2035713?dopt=AbstractPlus

176. Insel TR, Roy BF, Cohen RM et al. Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982; 139:954-5. http://www.ncbi.nlm.nih.gov/pubmed/7091416?dopt=AbstractPlus

177. Spigset O, Mjorndal T. Serotonin syndrome caused by a moclobemide- clomipramine interaction. BMJ. 1993; 306:248. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1676747&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/8443525?dopt=AbstractPlus

178. Cano-Munoz JL, Montejo-Iglesias ML, Yanez -Saez RM et al. Possible serotonin syndrome following the combined administration of clomipramine and alprazolam. J Clin Psychiatry. 1995; 56:122. http://www.ncbi.nlm.nih.gov/pubmed/7883731?dopt=AbstractPlus

179. Henry JA. Serotonin syndrome. Lancet. 1994; 343:607. http://www.ncbi.nlm.nih.gov/pubmed/7906365?dopt=AbstractPlus

180. Monteiro WO, Noshirvani HF, Marks IM et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry. 1987; 151:107-12. http://www.ncbi.nlm.nih.gov/pubmed/3315086?dopt=AbstractPlus

181. McLean JD, Forsythe RG, Kapkin IA. Unusual side effects of clomipramine associated with yawning. Can J Psychiatry. 1983; 28:569-70. http://www.ncbi.nlm.nih.gov/pubmed/6652610?dopt=AbstractPlus

182. Fraser AR. Sexual dysfunction following antidepressant drug therapy. J Clin Psychopharmacol. 1984; 4:62-3. http://www.ncbi.nlm.nih.gov/pubmed/6693585?dopt=AbstractPlus

183. Quirk KC, Einarson TR. Sexual dysfunction and clomipramine. Can J Psychiatry. 1982; 27:228-31. http://www.ncbi.nlm.nih.gov/pubmed/7201341?dopt=AbstractPlus

184. Riley AJ, Riley EJ. Cyproheptadine and antidepressant-induced anorgasmia. Br J Psychiatry. 1986; 148:217-8. http://www.ncbi.nlm.nih.gov/pubmed/3697592?dopt=AbstractPlus

185. Price J, Grunhaus LJ. Treatment of clomipramine-induced anorgasmia with yohmibine: a case report. J Clin Psychiatry. 1990; 51:32-3. http://www.ncbi.nlm.nih.gov/pubmed/2295589?dopt=AbstractPlus

186. Anand VS. Clomipramine-induced galactorrhoea and amenorrhoea. Br Psychiatry. 1985; 147:87-8.

187. Fowlie S, Burton J. Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine. Scott Med J. 1987; 32:52. http://www.ncbi.nlm.nih.gov/pubmed/3602989?dopt=AbstractPlus

188. Beaumont G. Sexual side-effects of clomipramine (Anafranil). J Int Med Res. 1973; 1:469-72.

189. Yassa R. Sexual disorders in the course of clomipramine treatment: a report of three cases. Can J Psychiatry. 1982; 27:148-9. http://www.ncbi.nlm.nih.gov/pubmed/7066846?dopt=AbstractPlus

190. Aizenberg D, Zemishlany Z, Hermesh H et al. Painful ejaculation associated with antidepressants in four patients. J Clin Psychiatry. 1991; 52:461-3. http://www.ncbi.nlm.nih.gov/pubmed/1744063?dopt=AbstractPlus

191. Myers BA, Klerman GL, Hartmann E. Nocturnal cataclysms with myoclonus: a new side effect of clomipramine. Am J Psychiatry. 1986; 143:1490-1. http://www.ncbi.nlm.nih.gov/pubmed/3777258?dopt=AbstractPlus

192. Pledger DR, Mathew H. Hyponatremia and clomipramine therapy. Br J Psychiatry. 1989; 154:263-4. http://www.ncbi.nlm.nih.gov/pubmed/2775959?dopt=AbstractPlus

193. Szarek BL, Goethe JW. Orthostatic hypotension as an indicator of response to clomipramine. Curr Ther Res. 1984; 36:54-7.

194. Ananth J, Assalian P. Intolerable side effects of clomipramine. J Clin Psychopharmacol. 1982; 2:215-6. http://www.ncbi.nlm.nih.gov/pubmed/7096611?dopt=AbstractPlus

195. Hermesh H, Aizenberg D, Weizman A et al. Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent. Drug Intell Clin Pharm. 1987; 21:877-9. http://www.ncbi.nlm.nih.gov/pubmed/3678059?dopt=AbstractPlus

196. Casas M, Garcia-Ribera C, Alvarez E et al. Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine. Int Clin Psychopharmacol. 1987; 2:333-6. http://www.ncbi.nlm.nih.gov/pubmed/3693873?dopt=AbstractPlus

197. Fukuzako H, Hokazono Y, Tominaga H et al. Jerk-locked averaging and somatosensory evoked potential in tricyclic-induced myoclonus: a case report. Japanese Journal of Psychiatry and Neurology. 1989; 43:645-9. http://www.ncbi.nlm.nih.gov/pubmed/2637391?dopt=AbstractPlus

198. Gersten SP. Tardive dyskinesia-like syndromes with clomipramine. Am J Psychiatry. 1993; 150:165-6. http://www.ncbi.nlm.nih.gov/pubmed/8417563?dopt=AbstractPlus

199. Domingo P, Munoz J, Bonastre M et al. Benign type of malignant syndrome. Lancet. 1989; 1:50. http://www.ncbi.nlm.nih.gov/pubmed/2563035?dopt=AbstractPlus

200. Chithiramohan RN, Ballard CG, Measey LG. Acute dystonia induced by clomipramine therapy. Irish Journal of Psychological Medicine. 1990; 7:141-2.

201. Bental E, Lavie P, Sharf B. Severe hypermotility during sleep in treatment of cataplexy with clomipramine. Isr J Med Sci. 1979; 15:607-9. http://www.ncbi.nlm.nih.gov/pubmed/478825?dopt=AbstractPlus

202. Moshe K, Iulian I, Seth K et al. Clomipramine-induced Tourettism in obsessive-compulsive disorder: clinical and theoretical implications. Clin Neuropharmacol. 1994; 17:338-43. http://www.ncbi.nlm.nih.gov/pubmed/9316681?dopt=AbstractPlus

203. Robinson ML. Epileptic fit after clomipramine. Br J Psychiatry. 1978; 132:525-6.

204. Hessov I. Hypertension during chlorimipramine therapy. Br Med J. 1971; 1:406. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1795008&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/5541936?dopt=AbstractPlus

205. Tunca Z, Tunca MI, Dilsiz U et al. Clomipramine-induced pseudocyanotic pigmentation. Am J Psychiatry. 1989; 146:552-3.

206. Marley J. Acute polyradiculoneuropathy after amitriptyline overdose. BMJ. 1987; 294:1616. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1246760&blobtype=pdf

207. Larrey D, Rueff B, Pessayre D et al. Cross hepatotoxicity between tricyclic antidepressants. Gut. 1986; 27:726-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1433318&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3721296?dopt=AbstractPlus

208. DeVries MW, Peeters F. Dental caries with longterm use of antidepressants. Lancet. 1995; 346:1640. http://www.ncbi.nlm.nih.gov/pubmed/7500792?dopt=AbstractPlus

209. Schlingemann RO, Smit AAJ, Verduyn Lunel HFE et al. Amaurosis fugax on standing and angle-closure glaucoma with clomipramine. Lancet. 1996; 347:465.

210. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatary. 1993; 54:289-99.

211. Lejoyeux M, Fineyre F, Ades J. The serotonin syndrome. Am J Psychiatry. 1992; 149:1410-1. http://www.ncbi.nlm.nih.gov/pubmed/1530086?dopt=AbstractPlus

212. Zohar J, Insel TR, Zohar-Kadouch RC et al. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988; 45:167-72. http://www.ncbi.nlm.nih.gov/pubmed/3276283?dopt=AbstractPlus

213. Benkelfat C, Murphy DL, Zohar J et al. Clomipramine in obsessive- compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989; 46:23-8. http://www.ncbi.nlm.nih.gov/pubmed/2910220?dopt=AbstractPlus

214. Flament MF, Rapoport JL, Murphy DL et al. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry. 1987; 44:219-25. http://www.ncbi.nlm.nih.gov/pubmed/3548637?dopt=AbstractPlus

215. Benkelfat C, Nordahl TE, Semple WE et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine. Arch Gen Psychiatry. 1990; 47:840-8. http://www.ncbi.nlm.nih.gov/pubmed/2393342?dopt=AbstractPlus

216. Swedo SE, Pietrini P, Leonard HL et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder: revisualization during pharmacotherapy. Arch Gen Psychiatry. 1992; 49:690-4. http://www.ncbi.nlm.nih.gov/pubmed/1514873?dopt=AbstractPlus

217. Pigott TA, Pato MT, Bernstein SE et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavior and biological results. Arch Gen Psychiatry. 1990; 47:926-32. http://www.ncbi.nlm.nih.gov/pubmed/2222131?dopt=AbstractPlus

218. Altemus M, Swedo SE, Leonard HL et al. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry. 1994; 51:794-803. http://www.ncbi.nlm.nih.gov/pubmed/7524463?dopt=AbstractPlus

219. Swedo SE, Leonard HL, Kruesi MJP et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1992; 49:29-36. http://www.ncbi.nlm.nih.gov/pubmed/1370197?dopt=AbstractPlus

220. Asberg M, Ringberger V, Sjoqvist F, et al Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther. 1977; 21:201-7. (IDIS 92830)

221. Bertilsson L Asberg M, Thoren P. Differntial effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression. Eur J Clin Pharmaol. 1974; 7:365-8.

222. Leonard HL, Meyer MC, Swedo SE et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995; 34:1460-8. http://www.ncbi.nlm.nih.gov/pubmed/8543513?dopt=AbstractPlus

223. Golden RN, Hsiao J, Lane E et al. The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab. 1989; 68:632-7. http://www.ncbi.nlm.nih.gov/pubmed/2537340?dopt=AbstractPlus

224. Golden RN, Ekstrom D, Brown TM et al. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry. 1992; 149:1168-75. http://www.ncbi.nlm.nih.gov/pubmed/1323933?dopt=AbstractPlus

225. Ackerman DL, Greenland S, Bystritsky A et al. Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive- compulsive disorder. J Clin Psychopharmcol. 1996; 16:324-8.

226. Sanchez LE, Campbell M, Small AM et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry. 1996; 35:537-44. http://www.ncbi.nlm.nih.gov/pubmed/8919717?dopt=AbstractPlus

227. Pers C, Kristiansen JE, Jonsson V et al. Rothia dentocariosa septicaemia in a patient with chronic lymphocytic leukaemia and toxic granulocytopenia. Dan Med Bull. 1987; 34:322-3. http://www.ncbi.nlm.nih.gov/pubmed/3436159?dopt=AbstractPlus

228. Piccinelli M, Pini S, Bellantuono C et al. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry. 1995; 166:424-43. http://www.ncbi.nlm.nih.gov/pubmed/7795913?dopt=AbstractPlus

229. Crisp AH, Lacey JH, Crutchfield M. Clomipramine and drive in people with anorexia nervosa: an in-patient study. Br J Psychiatry. 1987; 150:355-8. http://www.ncbi.nlm.nih.gov/pubmed/3664105?dopt=AbstractPlus

230. Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J. 1980; 56(Suppl 1):79-85. http://www.ncbi.nlm.nih.gov/pubmed/6994086?dopt=AbstractPlus

231. Fava M, Copeland PM, Schweiger U et al. Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am J Psychiatry. 1989; 146:963-71. http://www.ncbi.nlm.nih.gov/pubmed/2568763?dopt=AbstractPlus

232. Segraves RT. Reversing anorgasmia associated with serotonin uptake inhibitors. JAMA. 1991; 266:2279. http://www.ncbi.nlm.nih.gov/pubmed/1920732?dopt=AbstractPlus

233. Hollander E, McCarley A. Yohibine treatment of sexual side effects induced by serotonin reuptake blockers. JClin Psychiatry. 1992; 53:207-9.

234. Kennedy SH, Goldbloom DS. Current Perspectives on drug therapies for anorexia nervosa and bulimia nervosa. Drugs. 1991; 41:367-77. http://www.ncbi.nlm.nih.gov/pubmed/1711444?dopt=AbstractPlus

235. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Hardman JG, Limbird LE, Molinoff PB et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1995:431-59.

236. Furlanut M, Benetello P, Spina E. Pharmacokinetic optimisation of tricyclic antidepressant therapy. Clin Pharmacokinet. 1993; 24:301-18. http://www.ncbi.nlm.nih.gov/pubmed/8491058?dopt=AbstractPlus

237. Harper G. Suicidality with clomipramine. J Am Acad Child Adolesc Psychiatry. 1992; 31:369-70. http://www.ncbi.nlm.nih.gov/pubmed/1564041?dopt=AbstractPlus

238. Alarcon RD, Johnson BR, Lucas JP. Paranoid and aggressive behavior in two obsessive-compulsive adolescents treated with clomipramine. J Am Acad Child Adolesc Psychiatry. 1991; 30:999-1002. http://www.ncbi.nlm.nih.gov/pubmed/1757451?dopt=AbstractPlus

239. Ljunggren B, Bojs G. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features. Contact Dermatitis. 1991; 24:259-65. http://www.ncbi.nlm.nih.gov/pubmed/1831106?dopt=AbstractPlus

240. Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol Bull. 1995; 31:259-64. http://www.ncbi.nlm.nih.gov/pubmed/7491377?dopt=AbstractPlus

241. Lejoyeux M, Rouillon F, Ades J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatr Scand. 1993; 88:369-71. http://www.ncbi.nlm.nih.gov/pubmed/8296581?dopt=AbstractPlus

242. DeVeaugh-Geiss J, Moroz G, Biederman J et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial. J Am Acad Child Adolesc Psychiatry. 1992; 31:45-9. http://www.ncbi.nlm.nih.gov/pubmed/1537780?dopt=AbstractPlus

243. Berlin I, Cournot A, Zimmer R et al. Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects. Psychopharmacology. 1990; 100:40-5. http://www.ncbi.nlm.nih.gov/pubmed/2296627?dopt=AbstractPlus

244. Allen D, Curran HV, Lader M. The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects. Eur J Clin Pharmacol. 1991; 40:355-62. http://www.ncbi.nlm.nih.gov/pubmed/2050170?dopt=AbstractPlus

245. Ananth J, Pecknold JC, Van Den Steen N et al. Double-blind comparative study of clomipramine and amitriptyline in obsesive neurosis. Prog Neuropsychopharmacol. 1981; 5:257-62. http://www.ncbi.nlm.nih.gov/pubmed/7022517?dopt=AbstractPlus

246. Capstick N. Clomipramine in the treatment of the true obsessional state: a report on four patients. Psychosomatics. 1975; 16:21-5. http://www.ncbi.nlm.nih.gov/pubmed/1178805?dopt=AbstractPlus

247. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res. 1985; 14:85- 93. http://www.ncbi.nlm.nih.gov/pubmed/3887445?dopt=AbstractPlus

248. Waxman D. A general practitioner investigation on the use of clomipramine (Anafranil) in obsessional and phobic disorders: an interim report. J Int Med Res. 1973; 1:417-20.

249. Ananth J, Solyom L, Bryntwick S et al. Chlorimipramine therapy for obsessive-compulsive neurosis. Am J Psychiatry. 1979; 136:700-1. http://www.ncbi.nlm.nih.gov/pubmed/434251?dopt=AbstractPlus

250. Wyndowe J, Solyom L, Ananth J. Anafranil in obsessive compulsive neurosis. Curr Ther Res. 1975; 18:611-7. http://www.ncbi.nlm.nih.gov/pubmed/812637?dopt=AbstractPlus

251. Yaryura-Tobias, Neziroglu F. The action of chlorimipramine in obsessive-compulsive neurosis: a pilot study. Curr Ther Res. 1975; 17:111- 6. http://www.ncbi.nlm.nih.gov/pubmed/806424?dopt=AbstractPlus

252. Leonard HL, Swedo SE, Rapoport JL et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry. 1989; 46:1088-92. http://www.ncbi.nlm.nih.gov/pubmed/2686576?dopt=AbstractPlus

253. Pato MT, Hill JL, Murphy DL. A clomipramine dosage reduction study in the course of long-term treament of obsessive-compulsive disorder patients. Psychopharmacol Bull. 1990; 26:211-4. http://www.ncbi.nlm.nih.gov/pubmed/2236458?dopt=AbstractPlus

254. Carney MWP, Black P. A preliminary investigation of monochlor- imipramine in the treatment of depression. Int J Neuropsychiatry. 1967; 3:179-81. http://www.ncbi.nlm.nih.gov/pubmed/6043631?dopt=AbstractPlus

255. Gore CP. Clomipramine (Anafrail), Tofranil (imipramine) and placebo: a comparative study in relation to electroconvulsive therapy. J Int Med Res. 1973; 1:347-51.

256. Hynes MV. A comparative clinical trial of oral clomipramine (Anafranil) against amitrityline. J Int Med Res. 1973; 1:338-42.

257. Manna V, Martucci N, Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. Int Clin Psychopharmacol. 1989; 4(Suppl 1):81-8. http://www.ncbi.nlm.nih.gov/pubmed/2644342?dopt=AbstractPlus

258. Ropert R. Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol. 1989; 4(Suppl 1):89-95. http://www.ncbi.nlm.nih.gov/pubmed/2644343?dopt=AbstractPlus

259. Wolfersdorf M, Binz U, Wendt G et al. Double-blind study of oxaprotiline versus clomipramine in the treatment of depressive inpatients. Neuropsychobiology. 1987; 17:41-8. http://www.ncbi.nlm.nih.gov/pubmed/3306439?dopt=AbstractPlus

260. Kornhaber A, Horwitz IM. A comparison of clomipramine and doxepin in neurotic depression. J Clin Psychiatry. 1984; 45:337-41. http://www.ncbi.nlm.nih.gov/pubmed/6378895?dopt=AbstractPlus

261. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993; 9:133-45. http://www.ncbi.nlm.nih.gov/pubmed/8216696?dopt=AbstractPlus

262. Sundblad C, Modigh K, Andersch B et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992; 85:39-47. http://www.ncbi.nlm.nih.gov/pubmed/1546547?dopt=AbstractPlus

263. Eriksson E, Lisjo P, Sundblad C et al. Effect of clomipramine on premenstrual syndrome. Acta Psychiatr Scand. 1990; 81:87-8. http://www.ncbi.nlm.nih.gov/pubmed/2330836?dopt=AbstractPlus

264. Moline ML. Pharmacologic strategies for managing premenstrual syndrome. Clin Pharm. 1993; 12:181-96. http://www.ncbi.nlm.nih.gov/pubmed/8491076?dopt=AbstractPlus

265. Allen JE. Drug-induced photosensitivity. Clin Pharm. 1993; 12:580-7. http://www.ncbi.nlm.nih.gov/pubmed/8222522?dopt=AbstractPlus

266. Dale O, Hole A. Biphasic time-course of serum concentrations of clomipramine and desmethylclomipramine after a near-fatal overdose. Vet Hum Toxicol. 1994; 36:309-10. http://www.ncbi.nlm.nih.gov/pubmed/7975135?dopt=AbstractPlus

267. Linnoila M, Seppala T, Mattila MJ et al. Clomipramine and doxepin in depressive neurosis: plasma levels and therapeutic response. Arch Gen Psychiatry. 1980; 37:1295-9. http://www.ncbi.nlm.nih.gov/pubmed/7436691?dopt=AbstractPlus

268. Harrison W, Stewart J, McGrath PJ et al. Unusual side effects of clomipramine associated with yawning. Can J Psychiatry. 1984; 29:546. http://www.ncbi.nlm.nih.gov/pubmed/6541521?dopt=AbstractPlus

269. Murphy M. Down-regulation of post-synaptic serotonin receptors as a mechanism for clomipramine-induced anorgasmia. Br J Psychiatry. 1987; 151:704. http://www.ncbi.nlm.nih.gov/pubmed/3446321?dopt=AbstractPlus

270. Beaumont G. Sexual side-effects of clomipramine (Anafranil). J Int Med Res. 1977; 5(Suppl 1):37-44. http://www.ncbi.nlm.nih.gov/pubmed/863089?dopt=AbstractPlus

271. Zohar J, Zohar-Kadouch RC, Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs. 1992; 43:210-8. http://www.ncbi.nlm.nih.gov/pubmed/1372219?dopt=AbstractPlus

272. Ciba Geigy Limited, Pharmaceuticals Division. Anafranil (clomipramine hydrochloride) capsules brief prescribing information. In: MIMS Middle East. Surrey, UK: A.E. Morgan Publications Ltd.; 1996:86.

273. Haensel SM, Rowland DL, Kallan KT. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol. 1996; 156:1310-5. http://www.ncbi.nlm.nih.gov/pubmed/8808861?dopt=AbstractPlus

274. Balon R. Antidepressants in the treatment of premature ejaculation. J Sex Marital Ther. 1996; 22:85-96. http://www.ncbi.nlm.nih.gov/pubmed/8743620?dopt=AbstractPlus

275. Montorsi F, Guazzoni G, Trimboli F et al. Clomipramine for premature ejaculation: a randomized, double-blind, placebo controlled study. Acta Urol Ital. 1995; 9:5-6.

276. Ananth J, Pecknold JC, van der Steen N et al. Double-blind comparison study of chlorimipramine in obsessive neurosis. Curr Ther Res. 1979; 25:703-9.

277. Arfwidsson L, D Elia G, Laurell B et al. Comparison of chlorimipramine and imipramine in ambulatory treatment of depression. Acta Psychiatr Scand. 1972; 48:367-76. http://www.ncbi.nlm.nih.gov/pubmed/4571649?dopt=AbstractPlus

278. Cattiez PH, Dierick M, Troisfontaines B et al. Moclobemide (Ro 11- 1163) vs. clomipramine in the treatment of depression: a double-blind multicenter study in Belgium. Drug Develop Res. 1990; 21:325-331.

279. Chen CN. The use of clomipramine as an REM sleep suppressant in narcolepsy. Postgrad Med J. 1980; 56(Suppl. 1):86-9. http://www.ncbi.nlm.nih.gov/pubmed/7393833?dopt=AbstractPlus

280. Lipsedge MS, Prothero W. Clonidine and clomipramine in obsessive- compulsive disorder. Am J Psychiatry. 1987; 144:965-6. http://www.ncbi.nlm.nih.gov/pubmed/3605413?dopt=AbstractPlus

281. Golden RN, Morris JE, Sack DA. Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biol Psychiatry. 1988; 23:181-5. http://www.ncbi.nlm.nih.gov/pubmed/3334887?dopt=AbstractPlus

282. Guillbert E, Pelicier Y, Archambault JC et al. A double-blind, multicenter study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand. 1989; 350(Suppl.):132-4.

283. Ginestet D and the Multicenter Study. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol. 1989; 4(Suppl. 1): 37-40.

284. Gostik N, Beaumont G, Grieve A. Clomipramine and smoking: an interaction study- clinical findings. J Int Med Res. 1980; 8(Suppl. 3):85-7. http://www.ncbi.nlm.nih.gov/pubmed/7202823?dopt=AbstractPlus

285. Brasic JR, Barnett JY, Kaplan D et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994; 44:1309-12. http://www.ncbi.nlm.nih.gov/pubmed/8035936?dopt=AbstractPlus

286. McDougle CJ, Price LH, Volkmar FR et al. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992; 31:746-50. http://www.ncbi.nlm.nih.gov/pubmed/1644740?dopt=AbstractPlus

287. Segraves RT, Saran A, Segraves K et al. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther. 1993; 19:198-200. http://www.ncbi.nlm.nih.gov/pubmed/8246275?dopt=AbstractPlus

288. American Psychiatric Association. American Psychiatric Association Practice Guidelines. 1st ed. Washington, D.C.: American Psychiatric Association; 1996:52-53,96-102,110-111.

289. Carpenter LL, McDougle CJ, Epperson CN et al. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf. 1996; 15:116-34. http://www.ncbi.nlm.nih.gov/pubmed/8884163?dopt=AbstractPlus

290. Pigott TA. OCD: where the serotonin selectivity story begins. J Clin Psychiatry. 1996; 57(Suppl. 6):11-20. http://www.ncbi.nlm.nih.gov/pubmed/8647793?dopt=AbstractPlus

291. Harris MG, Benfield P. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging. 1995; 6:64-84. http://www.ncbi.nlm.nih.gov/pubmed/7696780?dopt=AbstractPlus

292. DeVeaugh-Geiss J. Pharmacologic therapy of obsessive compulsive disorder. Adv Pharmacol. 1994; 30:35-52. http://www.ncbi.nlm.nih.gov/pubmed/7833296?dopt=AbstractPlus

293. Dominguez RA, Mestre SM. Management of treatment-refractory obsessive compulsive disorder patients. J Clin Psychiatry. 1994; 55(Suppl.):86-92. http://www.ncbi.nlm.nih.gov/pubmed/7961537?dopt=AbstractPlus

294. Francois B, Marquet P, Desachy A et al. Serotonin syndrome due to an overdose of moclobemide and clomipramine: a potentially life-threatening association. Intensive Care Med. 1997; 23:122-4. http://www.ncbi.nlm.nih.gov/pubmed/9037653?dopt=AbstractPlus

295. Rihmer Z, Barsi J, Belso N et al. Antidepressant-induced hypomania in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1996; 11(Suppl. 5):203-5. http://www.ncbi.nlm.nih.gov/pubmed/8923100?dopt=AbstractPlus

296. Montgomery SA. Long-term management of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1996; 11(Suppl. 5):23-9. http://www.ncbi.nlm.nih.gov/pubmed/9032001?dopt=AbstractPlus

297. Fineberg N. Refining treatment approaches in obsessive-compulsive disorder. Int Clin Psychopharmacol. 1996; 11(Suppl. 5):13-22. http://www.ncbi.nlm.nih.gov/pubmed/9032000?dopt=AbstractPlus

298. DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit. 1997; 19:1-10. http://www.ncbi.nlm.nih.gov/pubmed/9029739?dopt=AbstractPlus

299. Mundo E, Bareggi SR, Pirola R et al. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol. 1997; 17:4-10. http://www.ncbi.nlm.nih.gov/pubmed/9004050?dopt=AbstractPlus

300. Lopez-Ibor JJ Jr, Saiz J, Cottraux J et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996; 6:111-8. http://www.ncbi.nlm.nih.gov/pubmed/8791036?dopt=AbstractPlus

301. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996; 16:356-62. http://www.ncbi.nlm.nih.gov/pubmed/8889907?dopt=AbstractPlus

302. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993; 53:84-8. http://www.ncbi.nlm.nih.gov/pubmed/8257462?dopt=AbstractPlus

303. Mills KC. Serotonin syndrome. Am Fam Physician. 1995; 52:1475-82. http://www.ncbi.nlm.nih.gov/pubmed/7572570?dopt=AbstractPlus

304. Reynolds RD. Serotonin syndrome: what family physicians need to know. Am Fam Physician. 1995; 52:1263-71. http://www.ncbi.nlm.nih.gov/pubmed/7572545?dopt=AbstractPlus

305. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994; 331:1021-2. http://www.ncbi.nlm.nih.gov/pubmed/8084345?dopt=AbstractPlus

306. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Safety. 1995; 13:94-104. http://www.ncbi.nlm.nih.gov/pubmed/7576268?dopt=AbstractPlus

307. Brodribb TR, Downey M, Gilbar PJ. Efficacy and adverse effects of moclobemide. Lancet. 1994; 343:475. http://www.ncbi.nlm.nih.gov/pubmed/7905962?dopt=AbstractPlus

308. Somerset Pharmaceuticals. Eldepryl (selegiline) tablets prescribing inforamtion (dated 1994 Sep). In: Physician s desk reference. 49th ed. Montvale, NJ: Medical Economics Company, Inc; 1995(Suppl. A):A157-8.

309. Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm. 1993; 12:222-5. http://www.ncbi.nlm.nih.gov/pubmed/8491079?dopt=AbstractPlus

310. American Psychiatric Association. DSM-IV™: diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994:417-23.

311. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986; 32:481-508. http://www.ncbi.nlm.nih.gov/pubmed/2878798?dopt=AbstractPlus

312. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy. 1987; 7:1-15. http://www.ncbi.nlm.nih.gov/pubmed/3554156?dopt=AbstractPlus

313. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol. 1987; 7(Suppl):36-43S.

314. Sulser F. Mode of action of antidepressant drugs. J Clin Psychiatry. 1983; 44:14-20. http://www.ncbi.nlm.nih.gov/pubmed/6406444?dopt=AbstractPlus

315. Mishra R, Janowsky A, Sulser F. Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in brain: effects of nisoxetine versus fluoxetine. Eur J Pharmacol. 1979; 60:379-82. http://www.ncbi.nlm.nih.gov/pubmed/316774?dopt=AbstractPlus

316. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Arch Gen Psychiatry. 1981; 38:1160-80. http://www.ncbi.nlm.nih.gov/pubmed/6271089?dopt=AbstractPlus

317. Banerjee SP, Kung LS, Riggi SJ et al. Development of β-adrenergic receptor subsensitivity by antidepressants. Nature. 1977; 268:455-6. http://www.ncbi.nlm.nih.gov/pubmed/197419?dopt=AbstractPlus

318. Bergstrom DA, Kellar KJ. Adrenergic and serotonergic receptor binding after chronic desmethylimipramine treatment. J Pharmacol Exp Ther. 1979; 209:256-61. http://www.ncbi.nlm.nih.gov/pubmed/220405?dopt=AbstractPlus

319. Wolfe BB, Harden TK, Sporn JR et al. Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther. 1978; 207:446- 57. http://www.ncbi.nlm.nih.gov/pubmed/213556?dopt=AbstractPlus

320. Maggi A, U’Prichard DC, Enna SJ. Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol. 1980; 61:91-8. http://www.ncbi.nlm.nih.gov/pubmed/6101555?dopt=AbstractPlus

321. Enna SJ, Kendall DA. Interaction of antidepressants with brain neurotransmitter receptors. J Clin Psychopharmacol. 1981; 1(Suppl):12-6S.

322. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980; 210:88-90. http://www.ncbi.nlm.nih.gov/pubmed/6251550?dopt=AbstractPlus

323. Kendall DA, Duman R, Slopis J et al. Influence of adrenocorticotropin hormone and yohimbine on antidepressant-induced declines in rat brain neurotransmitter receptor binding and function. J Pharmacol Exp Ther. 1982; 222:566-71. http://www.ncbi.nlm.nih.gov/pubmed/6286924?dopt=AbstractPlus

324. Peroutka SJ, Snyder SH. Regulation of serotonin₂(5-HT₂) receptors labeled with [³H] spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther. 1980; 215:582-7. http://www.ncbi.nlm.nih.gov/pubmed/6255132?dopt=AbstractPlus

325. Fuller RW. Functional consequences of inhibiting serotonin uptake with fluoxetine in rats. In: Ho BT, Schoolar JC, Usdin E, eds. Serotonin in biological psychiatry. New York: Raven Press; 1982:219-28.

326. Wong DT, Bymaster FP, Horng JS et al. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain:3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylprolylamine. J Pharmacol Exp Ther. 1975; 193:804-11. http://www.ncbi.nlm.nih.gov/pubmed/1151730?dopt=AbstractPlus

327. Wander TJ, Nelson A, Okazaki H et al. Antagonism by antidepressants of serotonin S₁ and S₂ receptors ofnormal human brain in vitro. Eur J Pharmacol. 1986;132:115-21.

328. Wong DT, Horng JS, Bymaster FP et al. A selective inhibitor of serotonin uptake: Lilly 110140,3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. LifeSci. 1974; 15:471-9.

329. Fuller RW, Perry KW, Molloy BB. Effect of 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine. JPharmacol Exp Ther. 1975; 193:796-803.

330. Fuller RW, Snoddy HD, Perry KW et al. Importance of durationof drug action in the antagonism of p-chloroamphetaminedepletion of brain serotonin—comparison of fluoxetine and chlorimipramine. Biochem Pharmacol. 1978; 27:193-8. http://www.ncbi.nlm.nih.gov/pubmed/623674?dopt=AbstractPlus

331. Westerink BHC, Lejeune B, Korf GE et al. On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs. Eur J Pharmacol. 1977; 42:179.

332. Baxter LR, Phelps ME, Mazziotta JC et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Arch Gen Psychiatr. 1987; 44:211-8. http://www.ncbi.nlm.nih.gov/pubmed/3493749?dopt=AbstractPlus

333. Swedo SE, Schapiro MB, Grady CL et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Am J Psychiatr. 1989; 46:518-23.

334. Baxter LR, Schwartz JM, Mazziota JC et al. Cerebral glucose metabolic rates in non-depressed patients with obsessive-compulsive disorder. Am J Psychiatr. 1988; 145:1560-3. http://www.ncbi.nlm.nih.gov/pubmed/3264118?dopt=AbstractPlus

335. Nordahl TE, Benkelfat C, Semple WE et al. Cerebral glucose metabolic rates in obsessive-compulsive disorder. Neuropsychopharmacology. 1989; 2:23-8. http://www.ncbi.nlm.nih.gov/pubmed/2803479?dopt=AbstractPlus

336. Hahan H, Ogren S. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol. 1981; 70:393-407. http://www.ncbi.nlm.nih.gov/pubmed/6262100?dopt=AbstractPlus

337. Delini-Stula A, Vassout A. Modulation of dopamine-mediated behavioral responses by antidepressants: effects of single and repeated treatment. Eur J Pharmacol. 1979; 58:443-51. http://www.ncbi.nlm.nih.gov/pubmed/574454?dopt=AbstractPlus

338. Chen CN. Sleep, depression and antidepressants. Br J Psychiatry. 1979; 135:385-402. http://www.ncbi.nlm.nih.gov/pubmed/231990?dopt=AbstractPlus

339. Faravelli C, Brat A, Marchetti G et al. Cardiac effects ofclomipramine treatment: ECG and left ventricular systolic time intervals. Neuropsychobiology. 1983; 9:113-8. http://www.ncbi.nlm.nih.gov/pubmed/6621851?dopt=AbstractPlus

340. Jones RB, Luscombe DK, Groom GV. Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J. 1977; 53(Suppl. 4):166-71. http://www.ncbi.nlm.nih.gov/pubmed/600893?dopt=AbstractPlus

341. Reviewer comments (personal observations).

342. Novartis, East Hanover, NJ: Personal communication.

343. Agency for Health Care Policy and Research. Management of cancer pain: clinical practice guideline. AHCPR publication No. 94-0592. Rockville, MD: Department of Health and Human Services; 1994 Mar.

344. Kloke M, Hoffken K, Olbrich H et al. Anti-depressants and anti- convulsants for the treatment of neuropathic pain syndromes in cancer patients. Onkologie. 1991; 14:400-3.

345. Abbott Laboratories. Tdx/TDxFLx tricyclic antidepressants assay. List No. 9681. (66-6424/R1). Abbott Park, IL; 1996 Feb.

346. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998; 18:84-112. http://www.ncbi.nlm.nih.gov/pubmed/9469685?dopt=AbstractPlus

347. Ballenger JC, Davidson JRT, Lecrubier Y et al. Consensus statement on panic disorder from the International Consensus Group on Depresion and Anxiety. J Clin Psychiatry. 1998; 59(Suppl 8):47-54. http://www.ncbi.nlm.nih.gov/pubmed/9707162?dopt=AbstractPlus

348. Food and Drug Administration. Class suicidality labeling language for antidepressants. From the FDA website:. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM161641.pdf

349. Food and Drug Administration. Public health advisory: suicidality in children and adolescents being treated with antidepressant medications. Rockville, MD; 2004 Oct 15. From the FDA website:. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161679.htm

350. Anon. FDA statement on recommendations of the psychopharmacologic drugs and pediatric advisory committees. Rockville, MD; 2004 Sep 16. From the FDA website:. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108352.htm

351. American Psychiatric Association (APA). APA responds to FDA’s new warning on antidepressants. Arlington, VA; 2004 Oct. 15. From the APA website:. http://www.psych.org/news_room/press_releases/04-55apaonfdablackboxwarning.pdf

352. American Academy of Child and Adolescent Psychiatry (AACAP). AACAP responds to the new FDA warnings on pediatric antidepressant medications. Washington, D.C; 2004 Oct 15. From the AACAP website:. http://www.aacap.org/cs/root/media/press_releases/2004_press_releases/aacap_responds_to_new_fda_warnings_on_pediatric_antidepressant_medication

353. American Academy of Pediatrics (AAP). Children, antidepressants and a black box warning. Washington, D.C; 2004 Oct. 15. From the AAP website:. http://www.aap.org/pressroom/aappr-pressreleases.htm

354. Food and Drug Administration. Medication guide: about using antidepressants in children or teenagers. Rockville, MD; 2005 Jan 16. From the FDA website:. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM161646.pdf

a. Mallinckrodt, Inc. Anafranil (clomipramine hydrochloride) prescribing information. Hazelwood, MO; 2001 Sept 5.

b. Volkmar F, Cook EH Jr, Pomeroy J et al for the American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 1999; 38(12 Suppl):32-54S.

c. AHFS drug information 2003. McEvoy GK, ed. Tricyclic antidepressants general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2003:2161-9.

d. Food and Drug Administration. FDA news: FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. Rockville, MD; 2007 May 2. From the FDA web site:. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm

e. Food and Drug Administration. Antidepressant use in children, adolescents, and adults: class revisions to product labeling. Rockville, MD; 2007 May 2. From the FDA web site:. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm

f. Food and Drug Administration. Revisions to medication guide: antidepressant medicines, depression and other serious mental illnesses and suicidal thoughts or actions. Rockville, MD; 2007 May 2. From the FDA web site:. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf

g. Bridge JA, Iyengar S, Salary CB. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007; 297:1683-96. http://www.ncbi.nlm.nih.gov/pubmed/17440145?dopt=AbstractPlus

h. National Institutes of Health Office of Medical Applications of Research. NIH consensus statement: diagnosis and treatment of depression in late life. 1991; 9;1-27.

i. Reynolds CF. Treatment of depression in late life. Am J Med. 1994; 97(Suppl 6A):39-46S.

j. Stewart RB. Advances in pharmactherapy: depression in the elderly—issues and advances in treatment. J Clin Pharm Ther. 1993; 18:243-53. http://www.ncbi.nlm.nih.gov/pubmed/8227232?dopt=AbstractPlus

k. Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr Scand. 1989; 80(Suppl 350):141-2.

Frequently asked questions

What are some common side effects of antidepressants?

More about clomipramine

Patient resources

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

7.9 / 10

293 Reviews

Images

Pill 0632 75mg is Clomipramine Hydrochloride 75 mg — Clomipramine Hydrochloride 75 mg (0632 75mg)